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Abstract Type 2 diabetes mellitus (T2DM) affects about 8% of the adult 
population worldwide, accounting for 90% of diabetes cases. This 
disease is caused by impairment of insulin signalling, leading to 
hyperglycaemia and compensatory hyperinsulinemia that result in a 
decrease in life quality and expectancy of patients. Even though it has 
mostly been associated with dietary and lifestyle risk factors, genetic 
factors of T2DM have been proposed, with increasing evidence.  
In order to study the transcriptional mechanisms involved in insulin 
signalling, I have analysed the livers of mice subjected to a 
fasting/refeeding program, after injection with insulin receptor 
antagonist S961 (to mimic insulin resistance) or PBS (control). To 
probe for feeding and insulin-regulated enhancers, Mediator (MED) 
complex recruitment was analysed. 
Data obtained suggest that Mediator complex occupancy is increased 
in the vicinity of feeding-upregulated genes. However, no novel 
enhancers were identified in association with recruited Mediator and 
further analyses are necessary to improve data quality. In parallel, 
S961 was assessed regarding its suitability as an insulin receptor 
antagonist. Although systemic and transcriptional effects of insulin 
signalling were blocked by S961, phosphorylation of Akt and GSK, 
downstream targets of the signalling pathway, suggested a partial 
agonist behaviour that should be clarified in future studies. 
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Palavras-Chave Resistência à insulina, resposta à alimentação, diabetes de tipo 2, 
S961, enhancer, complexo Mediador, regulação transcripcional, 
ritmos circadianos 
Resumo A diabetes mellitus de tipo 2 (DMT2) afeta cerca de 8% da 
população adulta mundial, representando 90% de todos os casos de 
diabetes. Esta doença é causada por uma resposta diminuída à ação 
da insulina, levando a hiperglicemia e hiperinsulinemia compensa- 
tória, que resultam numa diminuição severa da qualidade e espe- 
rança de vida dos pacientes. Apesar de ter sido associada à dieta e 
estilo de vida como fatores de risco principais, foram já propostos 
fatores genéticos da doença, com crescente apoio científico. 
Para estudar os mecanismos da transcrição envolvidos na resposta 
à insulina, analisei os fígados de ratinhos sujeitos a um programa 
de jejum/realimentação, após injeção do antagonista do recetor de 
insulina S961 (para simular resistência à insulina) ou PBS (usado 
como controlo). Para investigar e identificar enhancers regulados 
pela ingestão de alimentos e pela insulina, foi analisado o 
recrutamento do complexo Mediador (MED). 
Os dados obtidos sugerem que o complexo Mediador tem maior 
ocupação na proximidade de genes sobre-regulados pela ingestão 
de alimentos. No entanto, não foi possível identificar novos 
enhancers associados ao recrutamento do Mediador, e mais 
análises serão necessárias para melhorar a qualidade dos dados. 
Paralelamente, a conformidade do S961 enquanto antagonista do 
recetor de insulina foi avaliada. Apesar de os efeitos sistémicos e 
transcricionais da insulina serem bloqueados por este composto, os 
estados de fosforilação do Akt e da GSK, alvos da via de 
sinalização da insulina, são indicativos de um comportamento 
parcialmente agonista que deverá ser elucidado em estudos futuros. 
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Nøgleord Insulin resistens, fodringsrespons, type 2 diabetes, S961, enhancer, 
mediator komplekset, transkriptionel regulering, døgnrytme 
Resumé Type 2 diabetes mellitus (T2DM) rammer omkring 8% af alle voksne 
verden over og udgør endvidere 90% af alle diabetes tilfælde. 
Sygdommen er forårsaget af forringelse af insulin signaleringen, 
hvilket fører til hyperglycæmia og kompensatorisk hyperinsulinemia, 
resulterende i forværring af livskvaliteten samt formindskelse af den 
forventede levealder hos patienterne. Selvom T2DM mest er 
associeret med diæt og livstil, er der i stigende grad beviser for at 
genetiske faktorer også er involveret. 
For at undersøge de transkriptionelle mekanismer involveret i insulin 
signalering har jeg analyseret levere udtaget fra mus, der har været 
udsat for et faste/fodringsprogram og inden da er blevet injiceret med 
en insulin receptor antagonist S961 (for at simulere insulin resistens) 
eller PBS (kontrol). For desuden at identificere fodrings- og insulin-
regulerede enhancere blev rekruttering af mediator (MED) 
komplekset analyseret.  
Det indsamlede data antyder, at forekomsten af mediator komplekset 
er øget i nærheden af fodrings-opreguleret gener. Der er dog ikke 
identificeret nogle nye enhancere, der er associeret med rekrutteret 
mediator, og yderligere analyser vil være nødvendige for at forbedre 
kvaliteten af det indsamlede data. Desuden blev S961 undersøgt for 
sin evne som en insulin receptor antagonist. Selvom systematiske og 
transkriptionelle effekter af insulin signaleringen var blokeret af S961, 
så antyder fosforyleringen af Akt og GSK, der indgår i insulin 
signaleringskaskaden, at S961 opfører sig som en partiel agonist. 
Dette bør blive belyst yderligere i fremtidige studier. 
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 1. Introduction 
Type 2 Diabetes Mellitus (T2DM) is a chronic and progressive metabolic disease that, 
according to the World Health Organisation (WHO), affects about 8% of adults worldwide, 
with prevalence increasing at an alarming rate. T2DM comprises about 90% of all diabetes 
cases and is characterized by hyperglycaemia and compensatory hyperinsulinemia due to 
impairment of insulin signalling (insulin resistance)1. Due to the high prevalence of this 
disease, expected to almost double by 2030, and to its impact in life quality and expectancy, 
elucidating its underlying mechanisms and trying to find a cure for T2DM has become a 
high priority in research and healthcare1, 2. Although type 2 diabetes has been mostly 
associated with dietary and lifestyle risk factors, increasing evidence points to a genetic 
component dictating the development of the disease. Therefore, the identification of genetic 
mechanisms regulated by feeding and insulin signalling may be a crucial step in the path to 
make T2DM a more manageable, if not curable, disease, as genes showing impaired 
transcription in the insulin resistant state could be targets for treatment. 
1.1. Transcriptional machinery and epigenetic regulation in eukaryotes 
The transcription of all protein-coding genes is controlled by a common multiprotein 
complex that makes up the eukaryotic transcription machinery, RNA polymerase II (Pol II). 
DNA transcription is naturally repressed as a result of its organisation in nucleosomes, where 
the DNA helix is wrapped around histone octamers, but also of active protein complexes 
that maintain the repressive structure. This organisation forms a complex called chromatin3. 
Epigenetics is a term used to describe the regulation of gene expression through chromatin 
modifications not involving the sequence of DNA4. For a gene to become active, it has to be 
signalled by positive regulatory mechanisms, such as histone modifications (acetylation, 
phosphorylation, methylation), that open the chromatin structure and make the enhancer and 
promoter regions more accessible to the transcription enzymes3. Although phosphorylation 
and methylation have varying effects on the structure of chromatin, histone acetylation of 
enhancers (namely at H3K27) is usually associated with open chromatin and activated 
transcription5. While this is true for some modifications, in some cases histone-modifying 
enzymes are recruited through binding to components of the transcription initiation complex 
and therefore histone modification occurs after assembly of the transcriptional machinery6. 
Enhancer sites are dynamic regions of chromatin that drive transcription of target genes 
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through recruitment of activator proteins and transcription factors; they may be close or 
distant to the gene promoter5. Enhancers also differ in strength, which affects the frequency 
of transcriptional bursts at their target gene7. Initially, it was considered that the alteration in 
chromatin structure leading to the activated promoter was brought about through sliding of 
the nucleosomes, leaving the transcription start site (TSS) unoccupied, but with the modified 
histone octamers still in the chromatin structure in a different region3. However, more recent 
data have showed that removal and reassembly of the modified histones is a more accurate 
mechanism. This opening of the chromatin structure allows for the binding of RNA 
polymerase II and the remaining components of the transcription initiation complex: the 
general transcription factors (TFIIB, -D, -E, -F and -H) and the Mediator complex (described 
in section 1.3.)3, 8. Enhancer and promoter chromatin is enriched in histone variants that 
make the nucleosomes less stable and more prone to displacement from the DNA and to 
recruitment of DNA-binding proteins5. RNA Pol II is the enzyme responsible for promoting 
the high-fidelity synthesis of an mRNA molecule complementary to the DNA template 
strand on the active gene and proofreading the newly-synthesised mRNA transcript3, 8. The 
largest subunit of RNA polymerase II has a tail region consisting of multiple tandem repeats 
of a conserved heptapeptide rich in proline and serine residues, named carboxy-terminal 
domain (CTD)9. This ‘tail’ can be modified by multiple phosphorylations and is likely to 
have an essential role in regulating the transcriptional machinery and the assembly of the 
transcription initiation complex by interacting with the transcription factors10. 
Phosphorylation of the CTD may be necessary for the polymerase to go from transcription 
initiation to elongation and the Mediator complex has been reported to bind to the RNA Pol 
II through the CTD and stimulate its phosphorylation by the TFIIH kinase11, 12. Specifically, 
the polymerase is reported to be recruited to gene promoters where the preinitiation complex 
is assembling with the CTD hypophosphorylated; the CTD is then increasingly 
phosphorylated at the Ser5 residue during initiation and RNA Pol II proceeds to the 
elongation step within the gene, during which the CTD becomes additionally phosphorylated 
at Ser26, 13. 
The transcription factors recognise the promoter region and facilitate its unwinding: a 
subunit of TFIID helps the TATA box sequence of the promoter associate with TFIIB, which 
positions the DNA TSS near the active centre of the polymerase, stabilizes the newly-formed 
RNA and binds TFIIE; TFIIE then recruits TFIIH, that has helicase activity and unwinds the 
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target DNA; finally, TFIIF binds the non-template strand to avoid renaturing of the DNA 
helix while the template strand is transcribed at the active site, resulting in initiation of 
transcription. After synthesis of a sequence of 10 or more residues, the RNA molecule 
becomes stable enough for the transcription to progress; TFIIB is displaced and the 
polymerase can advance further downstream (promoter escape)3. 
1.2. The Mediator complex and MED1 activity 
The Mediator complex is a signal processor protein that can directly interact with RNA 
polymerase II and thus assists activator proteins bound at upstream enhancers in stimulating 
transcription14. It is a structure unique to the eukaryotic organisms that is required for 
transcription initiation at almost all eukaryotic Pol II promoters3, 8, 15. Despite its transversal 
function across eukaryote organisms, the primary structures (aminoacid sequence) of the 
Mediator subunits show extensive divergence; however, the 3D structure of the complex 
seems to be highly conserved. The subunits of this complex are organized into four modules: 
head and middle (bind to the polymerase), tail (interacts with the activator proteins) and 
Cdk8 (involved in the repression or activation of transcription due to its protein kinase 
activity that phosphorylates either the CTD or enhancer-bound activators, respectively)14, 16, 
17. Figure 1 shows a proposed structure for the Mediator complex, taking into consideration 
the established interactions between subunits. 
 
Figure 1. Structure of the Mediator complex, inferred from protein-protein 
interactions detected between its subunits (adapted from 16). 
Mediator acts as a bridge that interacts directly with an activator or repressor at 
transcriptional enhancer sites and with the transcription initiation complex at the gene 
promoter to elicit positive or negative regulation of gene expression14; it can act as a co-
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activator or co-repressor depending on the proteins that it binds to8, 15. Hence, activator 
proteins promote transcription through indirect interaction with the TFs and Pol II requiring 
the presence of Mediator; direct binding to transcription factors happens only in a few cases 
at a low extent. The effect of the Mediator complex on transcription regulation likely results 
from binding to Pol II through the CTD12, 18. Together, the Mediator complex and Pol II in 
association with the transcription factors make up the RNA polymerase holoenzyme12, 15, 19. 
Mediator is recruited to enhancers first and then promoters before binding of Pol II; also, 
unfolding of the complex to a crescent-like shape upon contact with activators seems to be 
required for interaction with the polymerase14, 15. RNA Pol II only binds to a Cdk8-free 
complex; Cdk8 is recruited later18. The promotion of transcription by Mediator results from 
TFIIH-dependent phosphorylation of the CTD of Pol II elicited by the binding of Mediator 
to an activator protein, followed by loss of the Cdk8 module and promoter escape of Pol II14, 
18, 20; binding to a repressor may lead to alterations of the CTD phosphorylation status 
producing the opposite effect on transcription11, 12. Mediator may also have additional roles 
in transcriptional regulation. In fact, it has been shown that Mediator interacts with a single 
nucleosome, and its protein Nut1 is likely involved in the acetylation of histone H321. 
Mediator was shown to be a crucial piece of the promoter-dependent transcriptional 
mechanism as no transcription occurs in its absence, even when the activator is present12, 15. 
Figure 2 illustrates the mechanism of action of the Mediator complex through indirect 
binding to the target DNA, by interacting with both activator and Pol II. 
 
Figure 2. Interactions established between the Mediator complex and the remaining components of the 
transcriptional machinery, as well as the activator/repressor proteins (A), and mechanism of action of the 
complex by bridging the enhancer and promoter sites (B) (from18). 
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Mediator of RNA polymerase II transcription subunit 1, or MED1, also known as TRAP220, 
is part of the Mediator complex. MED1 seems to promote both activation and repression of 
gene expression and may also be involved in the interaction between the Med2 subunit and 
the remaining subunits of the Pol II holoenzyme complex19. MED1 regulates transcriptional 
activation through binding to different nuclear receptors and other activators18, 22. As shown 
in figures 1 and 2, MED1 is located in the middle module of the Mediator complex and 
interacts with the subunit MED14 in the tail region, thus connecting these two modules16. 
Phosphorylation of the MED1 subunit by a member of the MAPK family leads to its 
stabilisation, association with the Mediator complex (through the MED7 subunit in the 
middle module) and activation to promote transcription23. Genome-wide ChIP-seq based 
experiments have shown that MED1 occupies active enhancers and particularly high 
enrichment of MED1 binding to chromatin has been associated with super-enhancers24. 
1.3. Circadian regulation of metabolism 
Most organisms have mechanisms to adapt to and predict periodic environmental changes, 
such as the 24h light/dark cycles, seasons or food availability, adjusting their activities and 
metabolic responses as a result of the time of the day25. One of those mechanisms is the 24-
hour internal circadian clock, which regulates sleep, feeding and metabolism, hormone 
secretion, among other processes. This allows for synchronism of cellular events at an 
organism level in anticipation of environmental cycles to maintain homeostasis. Disruption 
of the normal circadian and metabolic rhythms, for example due to shift work, sleep 
deprivation or night eating can have a severe health impact and result in metabolic diseases26, 
27. In fact, a rat rest-work model showed that night-shift work leads to a shift in feeding times 
and patterns that results in short-term altered metabolic gene expression in the liver, with 
some effects still prevailing after eight days of recovery28. As mentioned above, the 
epigenome (such as histone modifications and chromatin remodelling) alters and regulates 
gene expression, conferring it with plasticity to respond accordingly to the environmental 
conditions. Liver metabolism is highly influenced by these factors, as insulin is responsive 
to them (including nutrition and stress), and key metabolic enzymes are subject to epigenetic 
transcriptional regulation controlled by external signals26. There is not only regulation of 
metabolism by the epigenome, but the metabolic context of cells may also have an effect on 
epigenetic chromatin modifications4. 
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The internal clock machinery is composed of a central clock located in the hypothalamus 
that entrains several peripheral clocks located in most organs, including the liver, through 
neuronal and hormonal signals25, 26. The main central clock regulator is light, and peripheral 
clocks are quite susceptible to fasting/feeding cycles; as a consequence, metabolic tissues 
are especially sensitive to regulation by the peripheral clocks27. The protein components of 
the clock machinery are transcription regulators that modulate the oscillatory and tissue-
specific expression of their target genes and transcription factors, but may also affect their 
activity or stability or mediate a response by coactivators26. Clock proteins also recruit RNA 
Pol II and chromatin-modifying enzymes in a circadian pattern, modulating rhythmic histone 
acetylation and methylation, as well as promote chromatin remodelling, at both promoter 
and enhancer sites6, 13, 25. However, circadian regulation of cellular events is also a result of 
extensive post-transcriptional control, such as processing and degradation of mRNA6, 13. 
Genes involved in rhythmic hepatic function seem to be mostly regulated by the circadian 
regulation of transcriptional mechanisms described above, including Pol II recruitment and 
chromatin remodelling6. 
Metabolism is highly regulated by circadian clocks, and glucose homeostasis is particularly 
affected by the clock machinery; for example, the gluconeogenic key enzymes 
phosphoenolpyruvate kinase (Pck) and glucose 6-phosphatase (G6P) are direct targets of the 
clock machinery26. The circadian regulation of metabolism in the liver has been shown to 
depend on both fasting/feeding cycles (which depend on sleep/wake cycles, ultimately 
regulated by the central clock) and the action of peripheral clocks (also synchronised by the 
central clock mechanism)26, 29. Conversely, the availability of food and caloric intake also 
affects the fasting/feeding cycles, which can then alter the metabolic behaviour of the 
organism and regulate the peripheral clocks, specifically in the liver, and even uncouple 
them from the central mechanism25-27, 30. Feeding seems to be the main determinant of 
rhythmic gene-transcription in the liver, with the clock machinery enhancing the amplitude 
of oscillation and fine-tuning its timing, in anticipation of feeding patterns, which improves 
the efficiency of metabolic regulation28, 29, 31. 
1.4. Feeding response through the insulin signalling pathway 
As mentioned above, feeding is one of the main regulators of metabolism, through activation 
or repression of expression of central metabolic genes, due to the increase in available 
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nutrients after feeding. The liver has a central function in the regulation of metabolism, and 
in the adaptation to the transitions between feeding and fasting. Fasting stimulates 
glycogenolysis, gluconeogenesis, b-oxidation and ketogenesis, while refeeding quickly 
restores glycogen content, with glycolysis only taking place later on; hepatic glycogen is 
thus fundamental in maintaining glucose homeostasis32. Insulin is a polypeptide hormone 
secreted by the pancreatic b-cells in response to feeding (increased blood glucose), and 
acting mainly in the liver, muscle and fat tissues33. Although it is primarily regulated by 
feeding patterns, insulin secretion also exhibits a weak circadian rhythm and is stimulated 
by proteins of the intrinsic clock machinery26, 34. Besides maintaining glucose homeostasis, 
insulin is also involved in the regulation of lipid and protein metabolism as well as cell 
growth and differentiation2. 
Insulin exerts its cellular effects upon binding to the insulin receptor (IR), a glycosylated 
transmembrane tyrosine kinase receptor composed of two ab subunits (a2b2 tetramer). The  
a-chains from each subunit are linked to the b-chain on the same subunit and to each other 
by disulphide bonds35-37. Insulin binds at the extracellular a-chains and elicits activation of 
the enzymatic portion of the b-chains38. It has been proposed that there are two interacting 
binding sites that exhibit negative cooperativity36. Negative cooperativity is a concept that 
refers to the property of a receptor in which the binding affinity at a particular binding site 
is lowered when the remaining site(s) is (are) occupied by the ligand, as a result of 
cooperative site-site interactions that increase the dissociation rate constants of other sites. 
In fact, in the IR, sites occupied by insulin lower the affinity for insulin of the free sites37, 39. 
The accepted model of binding of insulin to the receptor is shown below, in figure 3. 
 
Figure 3. Model for the binding of insulin to the insulin receptor. The receptor is initially empty, 
in its inactive conformation (A); insulin binds first to binding site 1 on one of the monomers (B); 
then, upon binding to the second binding site, insulin promotes crosslinking between the IR 
monomers (high-affinity binding), thus activating the IR complex and promoting its auto-
phosphorylation (C); finally, a second insulin molecule might bind to the second pair of binding 
sites, but cannot promote its crosslinking (low-affinity binding) and therefore the receptor 
remains in the active conformation (D), (taken from 36).  
1130 
A B C D 
Fig. 4. Model for insulin binding to its receptor. (A) Empty receptor, (B) initial binding - SIR binding mode, (C) high-affinity binding - 
active complex, (D) low-affinity binding of second insulin molecule. The phosphorylation of the activated receptor is indicated in (C) and 
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Fig.5. Displacement of 'Z51-human insulin (-) and lZ5I-X92 (---) from hIR at 4°C with human insulin (O), X37 (A), and X92 
(M). Y-axis shows the absolute percent of bound tracer. 
this state, the binding energy arises from both binding-site 1 
and binding-site 2 interactions, and the contribution from 
each of the two sites may be different from the binding en- 
ergy pertaining to one-site binding, thus accounting for some 
of the differences between the relative affinities of the ana- 
logues for SIR and hIR. The bridging step may be the biolo- 
gically important one, giving rise to a conformational change 
which is transmitted through the cell membrane, activating 
the tyrosine kinase. If this step is slower for the binding-site- 
2 mutants than for human insulin, i.e. both k, and k, slower, 
this could explain the slow dissociation kinetics of these ana- 
logues (k4 rather than k, becomes rate determining) and the 
slow formation of the active complex might also be the 
reason for the low in-vitro potency of these analogues. Inter- 
estingly, naturally occuring insulins which display higher 
binding than potency (e.g. hagfish insulin [25] and hystrico- 
morph insulins [26, 271) have substitutions in the A13 and 
B17 positions. 
According to the model, the binding of insulin to the 
high-affinity site leaves a free binding-site 1 on one a subunit 
and a free binding-site 2 on the other. Thus, binding of a 
second molecule of insulin to the left-over binding-site 1 
could explain the curvilinear Scatchard plot of the holorecep- 
tor, since this binding site, in analogy with the soluble recep- 
tor, would be expected to have a significantly lower affinity. 
Usually the properties of the second binding site are difficult 
to examine directly since the binding is obscured by the 
much higher levels of binding to the high-affinity site. This 
problem was overcome using the high-affinity insulin ana- 
logue X92 as the tracer (Fig. 5). This analogue has a particu- 
larly high relative affinity for the soluble receptor which, 
according to the model, means an improved binding-site- 1 
contact. At an insulin concentration of 1 nM, where the 
high-affinity site is almost completely blocked (as seen in 
the curve with [TyrA14-'251]HI as tracer), the left-over bind- 
ing-site 1 binds > 90% of the [TyrA14-'251]X92. This is then 
displaced at higher concentrations of HI or X37. Conse- 
quently, when [TyrA14-'251]X92 is displaced with HI or X37, 
the displacement curve reflects the binding at the left-over 
binding-site 1 rather than binding to the high-affinity site. 
The affinity of this site as calculated from the displacement 
of [TyrA14-'251]X92 with HI is 1 nM which is close to the 
value found for SIR. The fact that the affinity of X37 for the 
low-affinity site is higher than that of HI further supports the 
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Insulin has two regions involved in binding to the receptor, located on opposite sides of the 
molecule, named binding sites 1 and 236. Some of the residues on insulin’s binding sites have 
also been shown to be involved in negative cooperativity, making up a “cooperative” site 
within it37. Similarly, each a-chain of the IR has two different binding sites, also termed 
binding sites 1 and 2. It then becomes apparent that activation of the IR by insulin requires 
interaction between the two subunits of the receptor, through insulin-mediated bridging of 
opposite binding sites from each a-chain, resulting in a high-affinity complex that leads to 
a conformational change of the IR36; the conformation of insulin also changes upon binding 
to the receptor37. The free binding site 1 in one of the a-chains could then bind to a second 
insulin molecule, but with significantly lower affinity and not leading to interaction with the 
free binding site 2 in the opposite chain36.  
Upon binding to its receptor, insulin elicits a change in its conformation and, subsequently, 
promotes auto-transphosphorylation of the tyrosine kinase portions of the IR on the internal 
part of the b-monomers, on multiple tyrosine residues, resulting on their activation36, 38, 
which leads to the propagation of the signalling pathway schematized in figure 4. Since the 
insulin-like growth factor 1 receptor (IGF-IR) is closely related to the IR, it also undergoes 
autophosphorylation following the binding of its ligand (IGF) and leads to the activation of 
the same cascade40. IR binds insulin with higher affinity than the IGF-1 receptor but, at high 
concentrations, insulin can also activate IGF-IR36, 37. 
 
 
Figure 4. Simplified schematic representation of the insulin signalling pathway, showing 
the central second messengers involved in the signal transduction after insulin binding to 
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the IR. Activation of the IR, a tyrosine kinase receptor, results in its auto-phosphorylation, 
which in turn elicits a phosphorylation cascade that ultimately leads to phosphorylation of 
Akt. Akt is a central signalling molecule that becomes active upon phosphorylation and 
proceeds to activate or inactivate downstream effector molecules (such as FOXO, mTOR, 
GSK) through phosphorylation, resulting in the cellular effects promoted by feeding and 
insulin signalling. There is also an alternative transduction pathway involving the MAPK 
cascade, which regulates various genes’ expression (adapted from 40). 
 
The active tyrosine kinase phosphorylates tyrosine residues of the insulin receptor substrate 
(IRS) proteins, which subsequently leads to the activation of two major phosphorylation 
cascades involved in different signalling events: the mitogen-activated protein kinases 
(MAPK) cascade, which ultimately promotes the expression of genes involved in the 
regulation of cell differentiation and proliferation, and the central Akt pathway40. Akt is 
phosphorylated by the kinase PDK1, through a mechanism initiated by PI3K enzymes 
phosphorylated by IRS proteins2. Phosphorylated Akt can then catalyse the phosphorylation 
of FOXO proteins, inhibiting their translocation to the nucleus and proapoptotic gene 
expression, and mTOR, promoting growth and protein synthesis. Phosphorylation by active 
Akt also promotes translocation of the muscle GLUT4 receptor to the cell membrane leading 
to increased glucose uptake, and induces inactivation of glycogen synthase kinase (GSK), 
allowing for hepatic synthesis of glycogen when glucose and insulin levels are high40. 
It should be noted that there are three different isoforms of Akt that seem to mediate distinct 
cellular processes: Akt1 has been associated with the regulation of somatic growth, while 
Akt2 appears to be involved in metabolism regulation, and specifically glucose homeostasis, 
and Akt3 may have a role in brain development2, 40. The diversity of cellular effects mediated 
by Akt seems to arise from the distinct functions of the three isoforms, despite their 
homology, which may be a result of, among others, different tissue distribution or different 
subcellular localization of the isoforms that conditions access to specific substrates, as 
appears to be the case of Akt2, in the regulation of glucose transport41. In fact, the different 
compartmentalization of each isoform within the cell, which seems to be independent of the 
phosphorylation status, has been verified: Akt1 is located mostly in the cytoplasm, Akt2 at 
the mitochondria and Akt3 in the nucleus42. 
Insulin resistance is a condition in which the cells are incapable of eliciting a normal 
response to the presence of insulin, resulting in generalized decreased glucose uptake and 
hyperglycaemia, as well as in increased synthesis of glucose, due to impairment of its 
suppression, and decreased glycogenesis in the liver. Compensatory hyperinsulinemia 
results from adaptation of the pancreatic b-cells to the high levels of blood glucose40. Besides 
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being hallmarks of type 2 diabetes, low insulin sensitivity (insulin resistance) and low 
glucose effectiveness (disposal mechanisms independent of high insulin) accurately predict 
the development of the disease and can precede diagnosis in prediabetic individuals by more 
than 10 years, independently of bodyweight43. A study involving Pima Indians (an ethnic 
group with high prevalence of T2DM) led to similar observations: insulin resistance was the 
strongest predictor of T2DM, but central distribution of body fat and high levels of fasting 
plasma glucose and insulin also preceded the onset of the disease44. However, insulin 
resistance can reveal selectiveness, and present repression of only some targets of insulin 
signalling, while others remain sensitive, which is evidenced by high levels of circulating 
lipids (free fatty acids and triglycerides)40. This can also be an effect of hyperinsulinemia on 
tissues and/or pathways not involved in glucose metabolism that may retain some sensitivity 
to insulin, such as the liver and the lipogenesis pathway. The phenotypical diversity of 
insulin resistance and T2DM may depend on the tissues and pathways affected2. 
1.5. Experimental models of insulin resistance and type 2 diabetes 
As type 2 diabetes is becoming more and more prevalent in nowadays society, use of 
accurate experimental models for insulin resistance and type 2 diabetes is essential for 
research on the molecular basis and pathogenesis of the disease, for the development of an 
efficient treatment and, eventually, discovery of a cure45. Biological and clinical research 
have had major developments largely due to the use of model organisms, the ones yielding 
high efficiencies being favoured for their short generation times, easy breeding or 
propagation, simple manipulation, inexpensiveness, wide availability and homology to 
human systems46. Model organisms have allowed identification of conserved core 
biochemical principles and processes and include vertebrate and invertebrate animals, plants, 
bacteria and fungi46. Rodent models, including the mouse (Mus musculus), are preferred in 
studies about human type 2 diabetes because of their biological similarities to human 
characteristics and disease, be it monogenic or polygenic; however, the multitude of clinical 
presentations of T2DM makes it hard to find the ideal model for any particular study45. 
Several models for insulin resistance have been proposed and put into practice, either based 
on a dietary, genetic, surgical or chemical/pharmaceutical approach2, 45, 47, 48. High-fat diet, 
for example, can affect the circadian period and clock rhythmicity, therefore also disrupting 
metabolism regulation26, and these effects can be exacerbated by frequent feeding or partly 
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reversed by time-restricted feeding and/or calorie restriction27, 29-31.  In vivo models have 
focused mainly on genetic manipulation of the insulin signalling pathway to clarify its 
mechanism of action. Tissue-specific knockouts of the insulin receptor (IR) have been 
particularly useful in determining the role of many tissues on insulin resistant organisms; 
liver insulin receptor knockout (LIRKO) mice have exhibited hyperglycaemia due to the 
inability of suppressing glucose production in the liver, compensatory hyperinsulinemia 
(aggravated by decreased hepatic insulin degradation), a decrease in lipid synthesis and 
secretion and in SREBP expression, and overexpression of the gluconeogenesis key enzymes 
phosphoenolpyruvate carboxykinase and glucose 6-phosphatase2, 49. The leptin deficient 
ob/ob mouse is another used model for insulin resistance, showing hyperinsulinemia, 
hyperglycaemia and a decrease in IRS and PI3K activity and Akt phosphorylation in the 
liver, but in this model the effects can’t be directly traced to changes in insulin signalling 
since the mice are hyperphagic and thus morbidly obese as well2. Therefore, different models 
lead to distinct changes in insulin signalling. In this project, we decided to take a 
pharmaceutical approach, using an antagonist molecule to the IR. Insulin receptor 
antagonism is commonly used to induce insulin resistance and can be achieved by binding 
of either antibodies or small peptides to specific sites that regulate the receptor’s activity47, 
48. Small peptides that have been artificially synthesized either agonize or antagonize the 
binding of insulin to its receptor, based on the structure of the IR and on its binding model. 
IR activation was only achieved using heterodimer peptides of the sites 1 and 2, not with 
homodimers that would promote site 1-site 1 or site 2-site 2 crosslinking. But orientation 
was also fundamental in determining the cellular effects of these molecules: site 2-1 dimers 
had mostly agonistic properties while site 1-2 dimers were antagonists50. S961 is a 
biosynthetic 43-aminoacid single chain site 1-2 peptide which shows insulin-antagonistic 
activity in vitro and in vivo through high-affinity and high-selectivity binding to the insulin 
receptor. This antagonist shows similar insulin receptor affinity and higher selectivity for IR 
over IGF-1 receptor, when compared to insulin itself51. Sprague-Dawley rats injected with 
S961 (10 or 30 nM/kg either subcutaneous, intravenous or intraperitoneally) exhibited a 
reversible increase in plasma glucose, which peaked 6h after injection, as well as a 
compensatory rise in serum insulin levels, and a long-term depletion of liver glycogen and 
body lipid storage, after prolonged exposure to S961 (injection of 10 nM/kg/day for 15 
days)52. These results illustrate the role of insulin signalling in glucose metabolism 
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regulation and provide significant evidence that S961 could be used as an experimental 
model for insulin resistance and for induction of type 2 diabetes hallmark features 
(hyperglycaemia, hyperinsulinemia, glucose intolerance, among others)51, 52. For these 
reasons, injection with S961 was the chosen method to induce insulin resistance in this 
project. However, there has been evidence that S961 is not a full antagonist of the insulin 
receptor, but rather a mixed agonist/antagonist, acting as a partial agonist at lower 
concentrations (1 to 10 nM) and as an antagonist at concentrations of 10 nM or higher. These 
results were observed in vitro only for IR and Akt phosphorylation and mitogenicity; 
glycogen synthesis and lipogenesis were fully antagonized by S96148. In a different study, 
the antagonistic effects of S961 were compared to those of the specific allosteric monoclonal 
antibody IRAB-B. This newly-developed antibody was shown to induce acute and prolonged 
insulin resistance in vitro and in vivo by decreasing IR and Akt phosphorylation and 
increasing glycaemia, but, in contrast to S961, doesn’t require repeat administration and 
binds even in the presence of insulin. S961 binds orthosterically and competes with insulin 
for the binding site, resulting in less expressive antagonistic effects at higher insulin 
concentrations47. The proposed model for binding of S961 to the IR shown in figure 5 may 
help explain these findings. 
 
Figure 5. Plausible model for the mechanism of binding of S961, shown as two connected yellow circles, to 
the active site of the insulin receptor (represented by the four blue circles), explaining how S961 may lead to 
different effects (agonistic or antagonistic behaviour) according to its concentration. In this model, low 
concentrations of S961 (1–10 nM) result in crosslinking of the receptor subunits in a similar way to insulin 
binding, mimicking its action, while higher concentrations allow for simultaneous crosslinking of the second 
pair of binding sites promoting an inactive conformation of the receptor and blocking insulin signalling. 
Insulin, as a less flexible molecule, can’t bring together the second pair of binding sites on the IR and thus 
only elicits the active conformation upon binding (adapted from 48). 
This model proposes that the IR has two identical monomers each containing a pair of partial 
binding sites (site 1 and 2) on the a-subunits, that are arranged antiparallelely, instead of 
symmetrically, as shown in figure 3. Insulin binding to a site 1 first, and then to the reciprocal 
one (site 2) on the other monomer would lead to crosslinking of the two a-subunits of the 
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receptor, which would become active, and the two-site binding model explains how S961 
could elicit different effects according to its concentration, with a bell-shaped dose-response 
curve48. However, this still doesn’t explain the fact that the agonistic effects only show in 
some cell processes but not in others. S961 was still chosen as the inducer of insulin 
resistance since high concentrations warrant antagonism of the insulin receptor and no other 
natural or modified ligands show antagonism of the IR. Novel monoclonal antibodies such 
as the IRAB may pose a viable alternative, but this antagonist was only reported when this 
project was already well underway. 
1.6. Project aims 
This project’s main goal was to identify insulin-regulated enhancers in liver tissue and 
potentially find transcription factors that respond to insulin signalling, regulate activity of 
enhancers and thus control transcription of insulin-responsive genes. Preliminary work from 
the Grøntved group suggested that the activity of several enhancers in the liver is modulated 
by feeding, but the effect of insulin signalling in the regulation of the activity of these 
enhancers should be clarified. This was done by using a mouse model of insulin resistance 
induced by a synthetic antagonist (S961) that allows to study the regulation of transcriptional 
plasticity in the liver in response to feeding. Besides, identification of genes, enhancers and 
transcription factors affected by the insulin resistant state was also a priority along this 
project, due to the high prevalence of type 2 diabetes in nowadays society. 
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2. Materials and methods 
In order to meet the goals set out for this project the following experimental setup was 
conceptualised and made into a scheme, as shown in figure 6. On the day of the animal 
experiment, mice were fed at their usual time (ZT11) and were subjected to S961 for 3 hours 
until sacrifice at ZT14. This scheme represents the initial plan for my project work; however, 
due to time limitations, it was not possible to conduct any experiments probing for H3K27ac. 
 
Figure 6. Experimental setup designed to identify enhancers involved in feeding and insulin response in the 
liver. Mice were trained to a fasting/feeding program for 3 days. On the day of the experiment, PBS/S961 was 
intraperitoneally injected at ZT11 (40 nM/kg). Then mice were fed/fasted and sacrificed at ZT14. 
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2.1. Animal experiment 
Eighteen C57BL/6N male mice were purchased aged 8 weeks old from Taconic Biosciences, 
Inc. The mice were kept in controlled temperature (21 ± 2 °C), humidity (40 - 65%) and light 
(12 h light / 12 h dark) settings. Experimental procedures were approved by the Danish 
Animal Experiments Inspectorate (Dyreforsøgstilsynet). 
After one week of acclimatization, mice were divided into single cages. Three days later, 
they were subjected to a fasting/feeding training program for three days, in which mice were 
fed (standard chow) only during the night period, with food being taken away at 8 a.m. and 
given back at 5.30 p.m. On the day of the experiment, at the end of the fasting period (ZT11), 
mice were weighed and randomly separated into two experimental groups. Mice from the 
first group were injected with PBS buffer (PBS, n=9) and mice from the second group with 
an S961 solution, an insulin antagonist (S961, n=9). Right after injection, food was given 
back only to 5 randomly selected mice from each group, resulting in four different treatment 
groups. Fed mice made up groups Fed+PBS and Fed+S961, while fasted mice made up 
groups Unfed+PBS and Unfed+S961. At ZT14, mice were sacrificed by cervical dislocation. 
After sacrificing the mice, blood glucose was measured (using a glucometer), blood was 
immediately collected and subsequently centrifuged for biochemical analyses in the serum, 
stomach and intestines were checked for abnormalities and the liver, epididymal white 
adipose tissue (eWAT) and inguinal white adipose tissue (iWAT) were collected, frozen in 
liquid nitrogen, preserved in dry ice and stored at -80 °C. 
2.2. Analysis of biochemical parameters in the serum 
Total blood was centrifuged at 10,000 rcf for 10 minutes, at room temperature, to obtain the 
serum. Corticosterone and insulin concentrations were measured in the serum of all the 
animals from every experimental group, by an ELISA assay (Ultra Sensitive Mouse Insulin 
ELISA kit, Crystal Chem Inc., cat. no. 90080; Corticosterone ELISA kit, Enzo Life Sciences 
Inc., cat. no. ADI-900-097). 
2.3. Liver sample preparation for protein extraction 
A small piece of liver, of approximately 30 mg, was shortly homogenized in 1mL of lysis 
buffer (containing Tris-HCl, glycerol, SDS, b-glycerophosphate, NaF, sodium 
orthovanadate and water) to which PMSF (200 µM, Sigma-Aldrich) and a protease inhibitor 
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cocktail (cOmplete tablet, EDTA-free, Roche) were added, using an IKA T10 standard 
Ultra-Turrax homogenizer. Samples were then subjected to a benzonase treatment, by 
adding 3 µL of benzonase to 1 mL of sample, mixing well (without vortexing) and leaving 
at room temperature (RT) for 15 minutes. After spinning down, the supernatant was kept 
and stored at -80 °C until further analysis. 
2.4. Total protein quantification in liver extracts 
Total protein concentration in the samples obtained (see 4.3.) was determined by the 
spectrophotometric BCA method modified by Lars Grøntved. The calibration curve was 
obtained by making measurements with bovine serum albumin (BSA) standards with 
different well-established concentrations. Samples and standards were loaded in 96-well 
microplates (10 µL), to which 200 µL of working solution (Pierce BCA Protein Assay Kit, 
Thermo Fisher Scientific) were added. Afterwards, plates were incubated for 30 minutes at 
37 °C and optical density values were determined at 562 nm in a FLUOstar® Omega 
microplate reader (BMG LabTech). An example calibration curve is presented as an 
appendix (Appendix C). 
2.5. Protein separation by SDS-PAGE electrophoresis 
Polyacrylamide gels (10%) were prepared by cross-polymerization of acrylamide and 
bisacrylamide (30%, 29:1, Carl Roth GmbH) in the presence of ammonium persulphate 
(APS, Sigma-Aldrich) and tetramethylethylenediamine (TEMED, Sigma-Aldrich) in 
denaturing conditions provided by the addition of the anionic surfactant sodium dodecyl 
sulphate (SDS, Invitrogen, 0.4%). Each gel was cast with 15 wells. Pre-cast SDS-PAGE gels 
could be stored at 4 °C for up to 2–3 weeks if kept in a wet setting. Samples and a molecular 
weight marker were loaded into the gels. The loaded volume of sample was calculated so 
that total protein would amount to 80 µg in each well. Samples from the same experimental 
group were pooled into the same well so that less gels were required. Total volume loaded 
into each well was 20 µL, after adding protein lysis buffer, bromophenol blue (to confer 
colour to the samples) and mercaptoethanol (to denature proteins by breaking disulphide 
bonds). The loading mix containing sample and mercaptoethanol was boiled for 3 minutes 
in a heating block (95 °C) and centrifuged (maximum speed, 3 minutes) before being loaded 
into the gels, to complete protein denaturation. After loading the gels with the denatured 
samples, the gels were placed in the electrophoresis apparatus, covered with running buffer 
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(1x TGS, BioRad Laboratories) and run under a constant electrical current (20 mA per gel, 
for 2–2.5 hours) until the tracking dye reached the bottom of the gel, to induce proper protein 
separation in each sample/track, according to its molecular weight. 
2.6. Protein analysis by Western blotting 
Proteins separated in the electrophoresis gels were then transferred to polyvinylidene 
fluoride (PVDF) membranes (Amersham Hybond P 0.45 PVDF, GE Healthcare Life 
Sciences), by putting each gel and its corresponding membrane into contact and applying an 
electrical current, under transfer buffer, to induce the transfer (1h run at 400 mA, 100 V). To 
confirm protein transfer from the gels to the membranes, the latter were stained with an 
Amido Black 10B solution. After scanning and washing with ddH2O to remove excess 
staining solution, the membranes (blots) were blocked with a 5% BSA solution in TBS (milk 
was not used due to probing of phosphoproteins), for 1 hour at RT or overnight at 4 °C, in 
gentle agitation, in order to avoid non-specific binding of the primary antibody to the 
membrane and minimize false positives. The membranes were then incubated overnight with 
a solution of the primary antibody specific for the protein to be analysed. Analysed proteins 
were b-tubulin as a positive control and native and phosphorylated b-IGF-IR, Akt, FOXO1A 
and GSK-3b. Antibodies used to probe for those proteins are described in table 1.  Before 
and after incubating the membranes with the primary and secondary (1h at RT) antibodies, 
they were washed 3x in 1x TBS, and then with 1x TBS-T (3x 10 minutes, under gentle 
agitation) to remove leftover blocking solution or primary/secondary antibodies. Finally, 
membranes were incubated with a solution containing luminol and hydrogen peroxide 
(Pierce ECL Western Blotting Substrate, Thermo Fisher Scientific), which, upon reaction 
with the HRP (horseradish peroxidase) conjugated with the secondary antibody, results in 
the production of light from the protein bands recognised by the antibodies. The light emitted 
was digitally registered by an ImageQuant LAS 500 scanner (GE Healthcare Life Sciences) 
or a ChemiDoc XRS+ scanner (BioRad Laboratories). After exposure and scanning of the 
membrane, it was possible to identify and relatively quantify the proteins associated with 
their respective antibodies. 
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Table 1. Specifications of the antibodies used to probe for the target proteins analysed by Western blotting. 
Analysed Protein Primary antibody Secondary antibody 
b-tubulin 
1:2500, mouse mAb, #05-661, 
Merck Millipore 
1:2000 HRP-anti-mouse Ab, #7076, 
Cell Signaling Technology (1) 
b-IGF-IR 
1:1000, rabbit pAb C-20, sc-713, 
Santa Cruz Biotechnology 
1:3000 HRP-goat anti-rabbit Ab, 
#7074, Cell Signaling Technology (2) 
p-b-IGF-IR 
(phospho-Ser256) 
1:1000, rabbit pAb, #3024S, 
Cell Signaling Technology (2) 
Akt 
1:1000, rabbit pAb, #9272S, 
Cell Signaling Technology (2) 
pAkt 
(phospho-Ser473) 
1:1000, rabbit pAb, #9271S, 
Cell Signaling Technology (2) 
FOXO1A 1:500, rabbit pAb, ab39670, abcam (2) 
pFOXO1A 
(phospho-Ser256) 
1:500, rabbit pAb, ab131339, abcam (2) 
GSK-3b 
1:1000, rabbit pAb, H-76, sc-9166, 
Santa Cruz Biotechnology (2) 
pGSK-3b 
(phospho-Ser9) 
1:1000, mouse mAb F-2, sc-373800, 
Santa Cruz Biotechnology (1) 
2.7. RNA extraction from liver samples 
RNA was extracted from liver samples using an in-house column purification procedure. A 
small portion of mouse liver (kept in dry ice to avoid thawing and tissue degradation), of 
approximately 10 mg, was weighed into a 2 mL Eppendorf tube for each sample and 
immediately homogenised in 700 µL of Isol-RNA Lysis Reagent (5PRIME), using an IKA 
T10 standard Ultra-Turrax probe. Samples were subsequently always kept on ice. 
Chloroform (0.2x volume of Isol) was added to the homogenised liver samples to allow for 
nucleic acids extraction. After an incubation period of 15 minutes (RT), the samples were 
centrifuged at 4 °C, 10,000 xg for 10 minutes. The upper aqueous phase, containing the 
RNA, was carefully retrieved (260 µL) to new 1.5 mL Eppendorf RNase-free tubes, which 
were then placed on ice to minimize endogenous RNase activity. The interphase (containing 
DNA) and lower organic phase (containing proteins) were discarded. Ethanol (96%, 0.6x 
volume of Isol) was added to the samples and this mix was transferred to EconoSpin columns 
(Epoch Life Science), which was centrifuged for 30 seconds at 13,000 xg, RT. Afterwards, 
the columns were washed 3 times with RPE buffer (Qiagen, 500 µL). Each wash was 
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followed by a spin at 13,000 xg for 30 seconds. Finally, the column was spun dry for 2 
minutes at 13,000 xg, RT and the ethanol was let evaporate at RT. The RNA trapped in the 
column was then eluted in DEPC-treated water (≥ 97%, Sigma-Aldrich, 30 µL) by 
centrifuging at 16,000 xg, RT, for 1 minute. The RNA solutions were transferred to 1.5 mL 
Eppendorf tubes. RNA concentration was measured on a 2 µL sample on the NanoDrop ND-
1000 Spectrophotometer (Thermo Fisher Scientific Inc.), and RNA samples were stored at -
80 °C. 
2.8. cDNA synthesis (reverse transcription) 
Using the RNA samples obtained from step 4.3. as template, I obtained cDNA samples 
suitable for real-time quantitative PCR (qPCR). For each sample analysed, the volume of 
sample amounting to 1 µg of RNA (according to the quantification of RNA described 
previously), 2 µL of 5x DNase buffer, 1 µL of DNase I (Invitrogen, 10 U/µL) and DEPC-
treated water to a total of 10 µL were mixed and incubated for 15 minutes at 37 °C to ensure 
that all remaining DNA was destroyed. Samples were placed on ice to minimize RNase 
activity (and thus RNA degradation) and random hexamers were added (Roche, 3 µg). After 
5 minutes of incubation at 85 °C, to inactivate the DNase enzyme and allow for base pairing 
between the hexamers and the RNA, samples were put back on ice and were added 5 µL 
First Strand buffer (Invitrogen), 2.5 µL DTT (Invitrogen, 100 mM), 1 µL DEPC-treated 
water, 2.5 µL dNTP mix (10 mM of each dNTP) and 1 µL Reverse Transcriptase (Invitrogen, 
200 U/µL). This mix was left at RT for 10 minutes and then incubated for 1 hour at 37 °C to 
ensure that the reverse transcription reaction was complete. At the end of the incubation 
time, double-distilled water (ddH2O, 290 µL) was added to each sample tube. cDNA samples 
were stored at -20 °C. 
2.9. Primer design for analysis of cDNA by PCR 
To perform qPCR on the DNA samples obtained from the isolated RNA, it was necessary to 
design some of the primers used to select the analysed sites. First, the gene location under 
analysis was found on the Ensembl Genome Browser, filtered for the mouse genome. Then, 
for the pre-mRNA primers, the full gene sequence (including both intron and exons) was 
obtained and copied to the Primer3 online software (v. 0.4.0) to pick primers from the DNA 
sequence. It was defined that primers should have a melting temperature in the range of 59–
 30 
61 °C and that the product size should be between 75 and 125 bp in length. The Santa Lucia 
salt correction formula was applied and complementarity and 3’ complementarity were 
limited to 1.0. Finally, the primer possibilities returned by the Primer3 software were 
checked for their melting temperatures, DG value (should be between -3 and -6 kcal/mol) 
and number of hairpins, primer dimers and self-dimers they could form on the 
OligoAnalyzer online tool (from IDT, Integrated DNA Technologies). The best candidate 
sets were selected and its sequences were BLAST’ed on the UCSC Genome Browser to 
assure they identified the target sequence. The primers were tested on a series of dilutions 
of a pooled cDNA sample from the Fed+PBS group (because their target genes were feeding-
upregulated) to obtain a Cp value vs. dilution curve and the primer set with the best efficiency 
(closest to 100%) was chosen. The details for the designed primers are shown in table 2. 
Table 2. Specifications of the primer set designed to analyse SREBP-1c mRNA expression in cDNA samples 
obtained from mouse livers through rt-qPCR. 
Oligo Sequence Start Tm (°C) % GC Any compl. 3’ compl. 
Left Primer GGGGTAAAGGTCGGCAAGGCA 16553 59.03 61.90 2.00 0.00 
Right Primer CAGCGGCAGGCTAGATGGTGG 16655 59.58 66.67 4.00 0.00 
The resulting primer set created an amplification product located in the SREBP-1c gene 
transcript with a length of 103 bp. The primer pair was then tested in a series of dilutions 
(1x, 2x, 4x, 8x, 16x) prepared from a cDNA sample belonging to the experimental group 
Fed+PBS (since this should be the group with higher SREBP-1c mRNA levels considering 
it is a feeding upregulated gene). The primer set had an efficiency of 91.2%. The way the 
primer efficiency is calculated after testing is demonstrated in Appendix B. 
2.10. Chromatin Immunoprecipitation (ChIP) 
Firstly, a DSG-DMSO-PBS (2 mM) crosslinking solution was prepared by diluting 400 µL 
of DSG-DMSO solution (0.5 M) per 100 mL of DSG-DMSO-PBS solution. DSG-DMSO 
solution was added to PBS very slowly, with extreme caution, at RT on full speed on the 
magnetic stirrer, to avoid DSG polymerization and subsequent precipitation. DSG-DMSO 
solution was made by dissolving DSG (ProteoChem, MW = 326,26 g/mol) in the appropriate 
amount of DMSO (Sigma-Aldrich, ≥ 99.5%) to achieve a concentration of 0.5 M. 
Liver samples (approx. 100 mg) were weighed and homogenised in 7 mL of a DSG-DMSO-
PBS solution, and then left rotating for 30 minutes at RT, to allow for crosslinking of protein-
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protein interactions between co-factors and transcription factors (TF) associated with the 
DNA. This first crosslinking step can be skipped if doing TF or histone modification ChIP, 
but it should always be included if doing co-factor ChIP. Afterwards, the pellet was spun 
down at 1300 rpm, 4 °C for 10 minutes and re-suspended in 7 mL PBS + 1% Formaldehyde 
(Sigma-Aldrich, 36.5–38%) for 10 minutes while rotating, to allow for crosslinking of DNA-
proteins (transcription factors) interactions. Then, 1 mL of glycine (1 M) was added to 
quench the crosslinking reaction and samples were centrifuged for 10 minutes at 1700 rpm, 
4 °C. The supernatant was discarded and the pellet was washed twice in 10 mL cold PBS. 
Each wash was followed by a centrifugation at 1700 rpm, 4 °C (10 minutes). 
Proceeding to the isolation of nuclei and preparation of chromatin, samples were diluted in 
5 mL ChIP lysis buffer 1 (1% SDS, 20 mM EDTA, 50 mM Tris-HCl pH 8) and incubated 
for 1.5 hours at RT, while rotating, to allow for cell lysis and nuclei release through 
membrane disruption. The nuclei were then centrifuged at 1700 rpm, 8-10 °C, for 10 minutes 
to precipitate. At proper nuclei release, the pellet should be cloudy. The pellet was washed 
twice in 10 mL cold PBS; each wash was followed by a centrifugation at 1700 rpm, 8-10 °C 
(10 minutes). Samples were again diluted, this time in 2 mL ChIP lysis buffer 2 (0.1% SDS, 
1% Triton, 150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl pH 8.0) + 1x PI + 1 µg/µL BSA, 
and then sonicated for 90 seconds on the Covaris ME220 focused ultra-sonicator (peak 
power 75; 10% duty factor; 200 cycles) to fragment the DNA crosslinked to TFs and co-
factors and centrifuged at 10,000 xg, 4 °C, for 1 minute to precipitate cell debris. Supernatant 
was transferred to new tubes, to which enough ChIP lysis buffer 2 + 1x PI + 1 µg/µL BSA 
was added to total 400 µL of sample. 5% of the volume of each sample was saved for input, 
enabling input-output analysis later on. 
In the meantime, while waiting for nuclei extraction, 2x 30 µL (for pre-clearing and for 
immunoprecipitation, IP) of raw Prot A/B beads (Santa Cruz, sc-2003) per sample were 
prepared. Since the beads come in 4x ethanol, 240 µL of bead solution was used for each 
sample. After being centrifuged at 700 xg for 1 minute to remove the ethanol, the beads were 
washed three times in 1 mL ChIP lysis buffer 2 and centrifuged at 700 xg for 1 minute after 
each wash, removing the supernatant. Finally, 2x 70 µL of ChIP lysis buffer 2 + 1x PI + 1 
µg/µL BSA per ChIP reaction was added to the beads, which were then incubated for at least 
30 minutes at 4 °C, while rotating, until needed for the next step. BSA ensures low non-
specific binding between beads and antibody. 
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For the chromatin IP step, the samples were first precleared by adding 100 µL of the beads 
solution previously prepared to each of the samples and letting them incubate for 30 minutes 
at 4 °C, while rotating, to avoid non-specific binding between some proteins and the beads 
in the absence of antibody and thus minimize background signal. Samples were then 
centrifuged at 700 xg for 1 minute and the beads (pellet) were discarded. Next, the IP 
reaction took place by adding the specific antibody (2 µg) and BSA (5 µL) to the cleared 
samples containing the target-protein, letting them incubate overnight at 4 °C, while rotating, 
and then adding 100 µL of beads solution to each sample, followed by an incubation time of 
3h at 4 °C, while rotating, to allow for binding of the protein-bound antibodies’ heavy chain 
to the beads. This part of the procedure, as well as the next one, should be executed in a cold 
room set at 4 °C. The antibody targeted MED1 (M-255, sc-8998, Santa Cruz Biotechnology). 
A washing step followed, with a total of 6 separate washes, to eliminate non-specific binding 
and remove DNA fragments not associated with beads and antibody (meaning it wasn’t 
originally bound to the target-protein). Before the first wash, samples should be centrifuged 
at 700 xg, 4 °C, for 1 minute, and supernatant should be discarded. All washes were done 
with 500 µL buffer at 4 °C for 5 minutes, while rotating, and followed by a spin-down at 
700 xg, 4 °C, for 1 minute. The sequence of washing buffers used is 2x #1; #2; #3; 2x #4, 
decreasing in concentration. 
Afterwards, samples were eluted and decrosslinked. Firstly, 500 µL of elution buffer (1% 
SDS, 0.1M NaHCO3) was added to each of the samples, but also to the input samples 
previously saved and stored at -20 °C (on these samples, the sample volume should be 
considered to the total volume, so only 480 µL were added). The elution buffer aids in the 
decrosslinking reaction and in the denaturation of proteins. Samples and input were let to 
rotate at RT for about 30 minutes. Samples were then spun-down at maximum speed to allow 
deposition of the protein/antibody-bound beads, now separated from the DNA, and the 
supernatant (containing the DNA still bound to some proteins) was transferred to new tubes, 
to which 5M NaCl (20 µL) was added to assist decrosslinking. The same amount of 5M 
NaCl was also added to the input tubes. After vortexing, all samples were let to decrosslink 
overnight at 65 °C. 
IP and input samples were then subjected to phenol-chloroform extraction of the DNA, by 
generation of an organic-aqueous phase, that separates DNA (water-soluble) from proteins 
and cell debris. 1 volume (500 µL) of Phenol Chloroform Isoamylalcohol (PCI, Sigma-
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Aldrich, 25:24:1 saturated with 10 mM Tris, pH 8.0, 1 mM EDTA) was added to all tubes 
(ChIP/input) to cause protein denaturation leading to a conformational change towards a 
hydrophobic-behaving structure (phenol) and allow for a sharper separation of the phases 
(chloroform). Isoamylalcohol is present to reduce the foaming caused by SDS added in 
previous steps. After thoroughly vortexing, mixing by inversion and centrifuging for 5 
minutes at maximum speed and RT, the aqueous upper phase was transferred to new tubes, 
to which 1 volume (approx. 460 µL) of chloroform was added. All samples were again 
thoroughly vortexed, mixed by inversion and centrifuged (5 minutes, max. speed, RT) and 
the aqueous upper phase was transferred to new tubes, to which 2 µL glycogen (2 µg/µL), 
40 µL sodium acetate (3M, pH 4.5) and 1 mL ice cold ethanol (100%) were added. Sodium 
acetate, as well as ethanol, neutralizes the negative charges in DNA, making it insoluble in 
water and allowing it to precipitate. Glycogen is insoluble in ethanol, precipitating along 
with DNA and making it easier to see the pellet. Samples were thoroughly vortexed, mixed 
by inversion and incubated for 1h at -20 °C, after which the DNA was precipitated by 
centrifuging at full speed, 4 °C, for 25 minutes. The supernatant was removed and the DNA-
containing pellet was washed with 200 µL ethanol (70%), to remove any remaining salts, 
and spun-down at maximum speed for 5 minutes at 4 °C. Supernatant was again removed 
and the ethanol was left to evaporate (samples were completely dry when the pellet became 
transparent and no longer white). The pellet was ressuspended in milli-Q water (ddH2O), 
with the volume depending on the intended analysis to be undertook. Samples were stored 
at -20 °C until further analysis by RT-qPCR or ChIP-seq. 
2.11. Primer design for ChIP-qPCR 
To perform rt-qPCR on the DNA samples obtained either from ChIP, it was necessary to 
design the primers used to select the analysed sites. First, the gene location under analysis 
was found on the UCSC Genome Browser, filtered for the mouse genome. From the tracks 
showing H3K27 acetylation on fed and unfed animals, I zoomed in the areas of the gene 
most likely to be transcriptionally active (seen as a valley flanked by peaks, indicating the 
location of a promoter or enhancer). The DNA sequence was viewed (with masking of 
repeats as N) and copied to the Primer3 online software (v. 0.4.0). Thereon, the process was 
similar to the one used for mRNA primers (melting temperature: 59–61 °C; product size: 
75–125 bp; Santa Lucia salt correction formula; complementarity and 3’ complementarity: 
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1.0). Again, melting temperatures, DG value (should be between -3 and -6 kcal/mol) and 
number of hairpins, primer dimers and self-dimers of each possibility was checked with the 
OligoAnalyzer tool (IDT, Integrated DNA Technologies) to select the most suitable sets. 
The sequences were BLAST’ed on the UCSC Genome Browser to make sure the target site 
was recognized and to get the exact chromosome location. The primers were tested on a 
series of dilutions of a pooled ChIP DNA input sample to trace a Cp value vs. dilution curve. 
The primer set with the best efficiency (closest to 100%) was chosen. 
2.12. Real-time qPCR (RT-qPCR) 
Real-time qPCR was performed on DNA samples obtained either from ChIP or from cDNA 
synthesis from RNA samples as described on section 4.4. or 4.5., respectively. Samples were 
loaded on 384-well plates. Firstly, a mastermix containing SYBR Green Mastermix (Fast 
Start Essential DNA Green Master, Roche, 3.5 µL), 5’ and 3’ primers (10 pmol/µL, 0.5 µL 
of each) specific for the analysed gene and ddH2O (0.5 µL) was prepared for each analysed 
gene. Then, prepared mastermixes were distributed in the plate (5 µL in each well) and 
samples were added to individual wells (2 µL, in duplicate, for each gene) after vortexing. 
The plate was carefully covered with a sealing foil and spun for 2 minutes at 1200 rpm. PCR 
reactions were run on the LightCycler® 480 Instrument II PCR machine (Roche) under the 
“SYBR Long Program” (95 °C/2 min and 45 cycles 95 °C/10 s; 60 °C/15 s; 72 °C/15 s). 
Melting curve analysis was performed by the machine while the samples were heated from 
60 to 95 °C for 10 minutes. Data was saved in .txt format showing Cp values for each 
sample/well. 
2.13. Evaluation of sonication efficiency on the Fragment Analyzer 
Efficiency of sonication was assessed on ChIP input samples through an automated capillary 
electrophoresis on the AATI (Advanced Analytical Technologies, Inc.) Fragment Analyzer™ 
to check if the ChIP samples had enough quality for sequencing. A 96-well non-skirted plate 
was loaded with 30 µL of each sample, 30 µL of 1 kb plus DNA ladder FS-SLR930-U100 
(on the last well of the last used row) and 30 µL of milliQ-water on every unused well of the 
partially-loaded rows. All loaded wells were then covered with one droplet of mineral oil, to 
avoid evaporation of the samples, and the plate was spun down at 1200 rpm, RT, for 1 
minute. The gel used (Gel2) was dsDNA 930 separation gel, to which 2 µL of intercalating 
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dye were added per 20 mL of gel, and the marker was a combination of 75 bp and 20,000 bp 
markers (FS-SMK930-003). With the waste tray empty, the buffer and marker trays full and 
all solutions and plates loaded on the appropriate trays of the Fragment Analyzer, the 
samples were run under the method “DNF 930-33-DNA 75-20000 bp_sonication test”, with 
a sample injection time of 3 to 10 seconds. 
2.14. Quantification of DNA in ChIP samples 
Before sequencing, it is necessary to know the concentrations of DNA in each ChIP sample 
so that enough amount is prepared. DNA concentrations were determined using the 
PicoGreen assay. 2 µL of each sample was loaded into a black 96-well plate with opaque 
bottoms and 98 µL of TE buffer (10 mM Tris + 1 mM EDTA, pH 8.0) was added to each 
used well. l-DNA standards were prepared by dilution of a 2 ng/µL stock solution to 
concentrations of 10, 5, 2.5, 1.25, 1, 0.5, 0.25 and 0 ng/100µL and 100 µL of each was loaded 
in the plate, in duplicate. Next, 17.5 µL of PicoGreen were mixed with 3.5 mL of previously 
prepared 1x TE buffer and 100 µL of this solution was added to each of the already loaded 
wells. Fluorescence was then measured in the FLUOstar Galaxy luminometer (BMG 
LabTech), using the “Fast Start” setup named “Pico Assay MS”. An example calibration 
curve for determination of DNA concentration is presented as an appendix (Appendix D). 
2.15. Sequencing of ChIP samples (ChIP-seq) 
Two pooled samples per experimental group (Fed+PBS and Unfed+PBS) were prepared so 
that each got material from three ChIP samples (corresponding to 2 individuals per pooled 
sample), amounting to 5 ng of DNA in total, and milli-Q water was added to total 30 µL. 
Samples were numbered SM2659 to SM2662. The samples showing outlier results in ChIP-
qPCR were excluded from sequencing. These pooled ChIP samples were then subjected to 
library preparation for Illumina® sequencing, conducted by Majken Siersbæk, post-Doc with 
the Grøntved group, which I observed. 
The first step consists of adding 20 µL of End Repair Mix to each sample and incubating at 
30 °C for 30 minutes, to blunt unpaired nucleotides (overhangs) into phosphorylated ends. 
Then, the DNA fragments present in the sample were size selected to isolate only the 
fragments with a length of approximately 200 to 300 bp. The Agencourt AMPure XP beads 
(Beckman Coulter) that size-selectively immobilise the fragments need to be equilibrated to 
 36 
RT and vortexed to resuspend before being used in a series of clean up steps. By first adding 
37.5 µL of beads to each sample and letting them incubate at RT for 5 minutes (0.75x clean 
up), the fragments larger than 300 bp become immobilised in the beads and can be discarded 
by placing the tubes in a magnetic stand for 5 minutes (RT) until samples look clear and 
transferring the supernatant to new tubes. Next, adding 50 µL of new beads to the 
supernatant (followed by 5 minutes of incubation at RT) allows for immobilization of 
fragments longer than 200 bp in the beads (> 1x clean up). These fragments can subsequently 
be recovered by keeping the beads and discarding the supernatant after 5 minutes on the 
magnetic stand at RT. Without removing the tubes from the magnetic stand, the beads should 
be washed twice with 175 µL of fresh 80% ethanol, leaving to incubate for 30 seconds each 
time and letting the beads dry at RT for 5 minutes after removing all ethanol on the second 
wash. DNA can then be eluted from the beads by dissolving and incubating them in 20 µL 
of Resuspension buffer for 2 minutes (RT). Another 5 minutes on the magnetic stands allows 
to save the supernatant containing the size-selected DNA fragments and discard the beads. 
Afterwards, 3’-ends are adenylated by adding 12.5 µL of A-tailing mix to the samples, which 
then are incubated for 30 minutes at 37 °C. This process leads to the addition of an adenosine 
monophosphate residue to the 3’-ends of the DNA fragments, which will facilitate ligation 
of an adapter sequence (hairpin). After incubation, 20 µL of Resuspension buffer are added, 
making up a total volume of 50 µL, and a new clean up step follows by adding 37.5 µL of 
beads to each sample, letting incubate for 5 minutes (RT) and discarding the supernatant 
(containing fragments shorter than 200 bp) after being left at the magnetic stand for 5 
minutes (1x clean up). Beads should then be washed in 175 µL of 80% ethanol. After 
removing the ethanol, beads were let to dry. DNA fragments were eluted from the beads by 
suspending and incubating them in 22 µL of Resuspension buffer for 2 minutes (RT). 
Supernatant was subsequently transferred to new tubes and beads were discarded. 
At this point, the ligation of a hairpin adapter to the 3’-adenylated and 5’-phosphorylated 
DNA fragments was promoted by incubation of the samples, at RT for 15 minutes, in an 
adapter ligation mix containing the ligase enzyme master mix and the hairpin adapters. After 
incubation, 1 µL of User Enzyme (New England Biolabs, 1000 U/mL) was added to each 
sample, and a new incubation period followed (37 °C, 15 minutes). Resuspension buffer (24 
µL, total volume of 50 µL) was again added, leading to another clean up step: 45 µL of 
beads, incubation at RT for 5 minutes (0.9x clean up), placement on the magnetic stand for 
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5 minutes and discarding of the supernatant, resulting in removal of adapter remains since 
only fragments longer than 200 bp had been immobilised in the beads. Samples were washed 
twice in 175 µL of 80% ethanol and then let to dry; then, DNA was eluted from the beads 
by adding 52 µL of Resuspension buffer and incubating the mixture for 2 minutes (RT). The 
supernatant was saved and transferred to new tubes and a new 0.9x clean up step followed 
(45 µL of beads, elution in 22 µL of Resuspension buffer). At the end, 20 µL of the eluted 
DNA solution should be transferred to new tubes. 
The DNA samples selected and purified by this procedure were then amplified by PCR, 
which selectively enrichs the sample in adapter-ligated DNA fragments. The samples (10 
µL) were added to 10 µL of a reaction mix consisting of: Q5 reaction mix (New England 
Biolabs), dNTPs (New England Biolabs, 10 mM of each), Q5 polymerase (New England 
Biolabs, 2000 U/mL), ultra-pure water, universal PCR primer (New England Biolabs) and 
index primer (New England Biolabs). 16 PCR cycles were run due to the low amount of 
starting material (5 ng of DNA), with the following settings: 98 °C/30 sec, 16 cycles 98 
°C/10 s; 65 °C/30 sec; 72 °C/30 sec and a final cycle at 72 °C for 5 minutes. At the end of 
the PCR reactions, 28 µL of Resuspension buffer were added to each sample and a 0.8x 
clean up step followed: 40 µL of beads; 5 minutes’ incubation at RT; magnetic stand for 5 
minutes; discarded supernatant; twice washing with 80% ethanol (175 µL); removal of 
ethanol; and drying of the beads. At last, the DNA fragments immobilised in the beads (> 
250 bp) were eluted in 22 µL of Resuspension buffer, incubated at RT for 2 minutes, placed 
on the magnetic stand for 5 minutes. 20 µL of supernatant were saved and transferred to new 
tubes; beads were discarded. 
Quality control of the sample library was done on the Fragment Analyzer, where a test was 
performed to guarantee the absence of adaptor dimers and of amplified fragments not 
belonging to the target size range. The samples were run under the setup “DNA 35-1500 
bp_ChIP_QC”. Besides that, the library concentration was determined using KAPA. 
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2.16. Data analysis and statistics 
Analysis of RNA-seq and ChIP-seq data was conducted using the programs Terminal, 
Filezilla, Microsoft Excel and RStudio. RNA-seq data files were retrieved from the server 
and converted using Terminal and Filezilla. Alignment of sequences was achieved by 
applying the STAR algorithm, using mm9 as animal model (reference genome) to map the 
data. Analysis of differential expression of sequenced genes was done with the open source 
software DESeq2 (from Bioconductor)53; sequencing analysis and motif discovery was 
performed with HOMER (Hypergeometric Optimization of Motif EnRichment, from Salk 
Institute, UCSD)54. Illustrations were made resorting to the program RStudio, using R 
language code. Data analysis of systemic parameters and RT-qPCR results was done in 
Microsoft Excel. Statistical significance of the differences between experimental groups was 
assessed by a Student’s t-test (two-tailed) and a p-value (or FDR) below 0.05 was considered 
significant. Results are shown as average ± standard deviation. Western blots were only 
qualitatively analysed. 
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3. Results and Discussion 
3.1. RNA-seq characterisation of feeding-regulated genes 
To provide a characterisation of the genes my research project is focused on, I started by 
analysing pre-existing RNA sequencing data from mice subjected to the same treatments as 
the ones applied on my animal experiment (see experimental setup in figure 6). The R-coding 
script created to analyse this data is shown in Appendix A. Sequenced reads from cDNA 
libraries were quantified at annotated genes using HOMER and analysed by DESeq2 to call 
statistically significant regulated genes by multiple testing, providing the false discovery rate 
(FDR). Genes with FDR<0.05 were considered differentially regulated. Figures 7 and 8 
show the results of the preliminary analysis of sequenced mRNA from all annotated genes, 
highlighting the feeding-regulated (figure 7, up-regulation in green and down-regulation in 
red) and insulin-regulated (figure 8, in blue) sites. 
 
Figure 7. Distribution of all genes analysed by RNA-sequencing (RNA-seq), with feeding-regulated 
genes highlighted (FDR<0.05 for Fed vs. Unfed groups). Feeding upregulated genes, located at 
the top of the plot, are shown in green, while feeding down-regulated genes, located at the bottom 
of the plot, are shown in red. 
 
Figure 8. Distribution of all genes analysed by RNA-sequencing (RNA-seq), with insulin-regulated 
genes highlighted (FDR<0.05 for Fed vs. Fed+S961 groups): shown in light blue (insulin 
regulation not associated with feeding response) and dark blue (overlap with feeding regulation). 
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From these scatter plots, it is possible to see that both feeding- and insulin-regulation occur 
mostly on highly-expressed genes, demonstrated by the high tag densities (log2(mean tag 
density) > 5), and that significant differential expression in response to both feeding and 
insulin signalling is more prevalent at large fold changes between fed and fasted states. From 
a total of 31,645 mRNA sequences, 1,884 genes are regulated by feeding (about 6%), and 
846 of those show up-regulation. My project’s focus is on these positive regulated genes, 
which comprise about 45% of the feeding-regulated genes and 2.7% of all sequenced genes. 
Furthermore, I am looking to identify genes and transcriptional enhancers associated with 
insulin regulation. 325 genes are affected by S961 injection immediately before feeding, 
which corresponds to 1% of the total analysed genes. From further analysis (data partially 
shown to avoid excessive overlapping of points and crowding of the plot; see appendix A 
for extra plots), it was also possible to observe that only about half of the S961-regulated 
sites are located in the feeding-regulated areas of the plot, showing that some feeding-
independent genes are regulated by S961 (which could or could not correspond to regulation 
by insulin). This could point to some artefacts created by this drug or to activation of 
alternative signalling pathways by S961. For example, S961 may affect insulin signalling in 
adipose tissue which may affect gene expression in the liver. S961/insulin regulation 
overlaps with feeding-mediated regulation of transcription in 151 genes, which corresponds 
to 0.5% of all genes, or 8% of all feeding-regulated genes. 
Afterwards, since the focus of this project lies on the feeding up-regulated genes, I decided 
to analyse only these genes and highlight the insulin-regulated genes (figure 9). 
 
Figure 9. Focus on the feeding up-regulated genes, with S961-regulated genes (FDR<0.05 for 
Fed vs. Fed+S961 groups) highlighted in green. 
 
Forty-eight of the 846 genes upregulated in response to feeding are also regulated by S961 
and thus presumably by insulin. This corresponds to 5.7% of feeding-upregulated genes, or 
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2.5% of all feeding-regulated genes (0.2% of the total of analysed genes). Therefore, only a 
minority of the feeding regulated genes in the liver are deregulated upon systemic insulin 
resistance (2.5%). This apparently low percentage of insulin regulation of cellular effects of 
feeding could either indicate that there’s significant regulation by alternative mehanisms 
(such as direct regulation by glucose) or be a result of artefacts of the action of S961 (the 
antagonist), as it may not antagonize all of insulin’s effects on transcription. It can also derive 
from the systemic effects of S961, such as hyperinsulinemia, which might activate other 
regulatory pathways, independently of activation of the receptor. 
Finally, the same data was organised in a way to show the effect of administrating the insulin 
antagonist S961 to fed mice on the feeding-upregulated genes (figure 10).  
 
Figure 10. Distribution of feeding up-regulated genes in terms of insulin regulation. S961 up- 
and down-regulated genes are highlighted in green. 
From this plot, it is possible to see that there are 3 genes that, though being up-regulated by 
feeding, are down-regulated by the action of insulin. Moreover, 2 of these 3 genes (Klf10 
and E2f8) encode for transcription factors, which can show that insulin regulation may also 
have an indirect action on gene expression by altering the expression of transcription factors 
that will later modulate the expression of other feeding-regulated genes. The third gene 
(Slc25a30) encodes for a mitochondrial solute carrier protein. The 45 feeding upregulated 
genes that are repressed by S961 (thus presumably upregulated by insulin as well) include 
Srebf1 (sterol regulatory element-binding protein), Sqle (squalene epoxidase), Gck 
(glucokinase) and Pik3r1 (phosphatidylinositol 3-kinase regulatory subunit alpha) as some 
of the most feeding and insulin upregulated genes of the set. All of these genes are 
metabolism regulators. Srebf1 and Sqle encode for proteins involved in sterol biosynthesis, 
while Gck encodes for a key enzyme of glucose metabolism and Pik3r1 is a central 
messenger molecule in the insulin signalling pathway. Also, Gck, Srebf1 and Pik3r1 are well 
known targets of the insulin receptor signalling pathway. 
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3.2. Systemic evaluation of sacrificed mice 
In order to characterise the systemic insulin resistant state of the animals injected with the 
insulin antagonist S961, each mouse’s blood glucose was measured immediately after 
sacrifice. The mice were also weighed prior to injection with either PBS or S961 to account 
for their initial state after acclimatisation and before the experiment was carried out. The 
results are shown in table 3. 
Table 3. Mice body weight at the beginning of the experiment (after acclimatization) and effect of feeding 
and/or injection with insulin antagonist S961 in blood glucose (results are shown as average ± standard 
deviation). Experimental groups (for future reference): Fed+PBS (normal fed animals); Fed+S961 (insulin-
resistant fed animals); Unfed+PBS (normal fasted animals); Unfed+S961 (insulin-resistant fasted animals). 
Experimental Groups Body weight (g) S961 injection PBS injection Blood glucose (mM) 
ZT14 Unfed + PBS 21.18 ± 4.36 – √ 6.12 ± 1.34 
ZT14 Unfed + S961 22.08 ± 1.84 √ – 11.59 ± 2.92* 
ZT14 Fed + PBS 23.12 ± 1.66 – √ 6.34 ± 1.04 
ZT14 Fed + S961 22.30 ± 1.23 √ – 17.65 ± 2.99+ 
   * p < 0.05 vs Unfed+PBS; + p < 0.05 vs Fed+PBS 
The initial body weight did not show any significant differences between experimental 
groups, as seen on the data shown in table 3, which suggests a uniform acclimatization across 
all individuals and random attribution of mice to experimental groups and thus rules out the 
possible influence of body weight on insulin action. As expected, the administration of S961, 
a known antagonist of insulin, caused a significant increase in blood glucose relatively to 
the relevant control group, injected with PBS, as described in previous studies52. This 
increase reflects the blocking of the insulin receptor and decreased glucose uptake, and is a 
good indicator that insulin resistance has been induced on the S961-injected mice, since 
insulin signalling has been blocked and thus glucose is not incorporated into the cells. 
3.3. Analysis of serum biochemical parameters 
The serum samples analysed in this project were obtained by centrifuging the clotted blood 
and saving the serum (liquid portion). The concentrations of insulin and corticosterone were 
determined in the serum of the mice from every experimental group, by means of ELISA 
assays, to test the suitability of the insulin resistance animal model through evaluation of the 
systemic effects of feeding and insulin antagonist S961. The results are shown in figure 11. 
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Figure 11. Effect of feeding and/or injection with insulin antagonist S961 on the levels of serum insulin (A) 
and serum corticosterone (B). Results are shown as average ± standard deviation.  
 *** p < 0.001 vs. Unfed+PBS; +++ p < 0.001 vs. Fed+PBS; # p < 0.05 vs. Unfed+S961 
As can be seen in figure 11-A, both feeding and administration of the insulin antagonist S961 
cause an increase in the levels of serum insulin, as expected and previously shown52. The 
increase in serum insulin after feeding on control groups (injected with PBS) can be 
explained by the normal physiological response to the increased levels of blood glucose 
achieved after a meal, where the pancreatic b-cells produce and release insulin in order to 
stimulate the tissues to take up glucose from the blood and metabolise it to produce energy 
for the body or to create stores as glycogen. On the other hand, the increase in insulin levels 
after administration of S961 in both Fed and Unfed groups should indicate the proper 
blocking of the insulin receptor on the target tissues by the insulin antagonist (S961), since 
this would inactivate the insulin signalling pathway, thus limiting the uptake of glucose by 
the cells and leading to an accumulation of glucose on the blood, which would then trigger 
a compensatory mechanism in which pancreatic b-cells over-produce insulin to try to lower 
blood glucose levels, resulting in hyperinsulinemia40. 
Figure 11-B shows a decrease in corticosterone levels in the serum with feeding in both 
control and S961 groups. Being a glucocorticoid hormone, corticosterone is a stress-reponse 
hormone and it is also involved in glucose metabolism regulation. Its release is stimulated 
by stress and by low blood glucose, which conforms with the observed results. 
Glucocorticoid hormones, best represented by cortisol, have a contrary effect to insulin and 
are known to promote gluconeogenesis in the liver and inhibit glucose uptake in the muscle 
and adipose tissue during fasting, to restore blood glucose levels. Cortisol also indirectly 
stimulates glycogenolysis in the liver through glucagon activation. Besides that, previous 
results from the Grøntved group have shown an increase in corticosterone levels just before 
feeding time, and other studies have suggested a diurnal variation in the levels of cortisol55, 
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with peaks at the start of the active period, just before feeding. Therefore, the increased 
corticosterone levels observed in the fasted groups in figure 11-B seem to result from a 
normal response to lowered blood glucose and, possibly, from a circadian anticipation of 
feeding. Also, the higher levels of corticosterone in the fasted groups in contrast with the 
absence of a significant difference with administration of S961 in either Fed or Unfed groups 
could show that all animals were subjected to the same basal level of stress during handling 
and euthanasia, and that the fasting period was the only relevant source of stress during the 
experiment, minimising the influence of stress levels on the metabolism regulation and 
associated signalling pathways. 
3.4. RT-qPCR analysis of RNA expression 
Besides characterising the feeding- and insulin-regulated genes by statistical analysis of 
RNA-seq data, and analysing anthropometric and serum parameters, I also evaluated the 
differential expression of canonical feeding-regulated genes (involved in metabolism 
regulation) by qPCR analysis on samples of cDNA synthesised from RNA extracted from 
the liver. I intended to check if the inhibition of insulin signalling was producing the 
expected results on gene expression in the liver, and thus validate the RNA-seq data. Results 
are shown in figures 12 to 14. 
 
Figure 12. Effect of feeding and/or insulin antagonist S961 on the mRNA expression levels of 
transcription factor IIB, or TFIIB, evaluated by rt-qPCR in liver tissue. Results are shown as 
replicate average ± standard deviation. 
From figure 12, it is possible to verify that there is little variation in the mRNA levels of 
transcription factor IIB (TFIIB, a ubiquitously expressed gene) among individuals, even 
belonging to different experimental groups. This not only serves as a positive control, but 
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also shows that cDNA synthesis was fairly uniform among all samples, and thus provides a 
reliable basal level against which other genes’ expression can be normalized. Therefore, in 
this experiment, TFIIB can be used as a reference gene. 
In order to evaluate the normal functioning of the chosen animal model, and thus assess the 
differential expression of well-known feeding-regulated genes in the liver, mRNA 
expression levels of specific sequences (transcripts) were evaluated via RT-qPCR. I focused 
on well-known and highly regulated genes involved in glucose (Gck, G6Pc, Pck1) and lipid 
metabolism (SREBP-1c). Even though the focus of my study lies on feeding-upregulated 
genes, for this purpose I chose two genes that are upregulated and two that are downregulated 
by feeding to get a better insight into the way the antagonist works and the effect of feeding 
and insulin on the expression of such genes. Results obtained are shown in figures 13 and 
14. Figure 13 focuses on the differential expression of two feeding-upregulated genes (Gck 
and SREBP-1c) in response to feeding and/or insulin antagonist S961, while figure 14 shows 
the effect of the same treatments on two feeding-downregulated genes (G6Pc and Pck1). 
 
Figure 13. Effect of feeding and/or insulin antagonist S961 on the mRNA expression levels of two canonical 
feeding-upregulated genes, coding for glucokinase, or Gck (A), and the catalytic subunit of the sterol 
regulatory element-binding protein, or SREBP-1c (B), in the liver, evaluated by rt-qPCR. Results are shown 
as group average ± standard deviation.  
 *** p < 0.001 vs. Unfed+PBS;  ** p < 0.01 vs. Unfed+PBS;  
              +++ p < 0.001 vs. Fed+PBS;  # p < 0.05 vs. Unfed+S961 
The plots in figure 13 show two feeding up-regulated genes. Glucokinase (Gck) is the 
enzyme that catalyses the first reaction of glycolysis, a key regulatory step in glucose 
metabolism, and of glycogen synthesis. Glucokinase is therefore highly expressed after 
meals to enable storage and, later, breakdown of the available glucose. Sterol regulatory 
element-binding proteins (SREBPs) are transcription factors that bind to the sterol regulatory 
element sequence in DNA in response to low levels of sterols to stimulate expression of 
enzymes involved in sterol synthesis, which are essential for fat anabolism (namely, 
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cholesterol and fatty acid synthesis). SREBP-1c, the liver-specific isoform, which responds 
to insulin signalling, is particularly important in regulating lipogenesis after feeding49. From 
the results, it is clear that both Gck and SREBP-1c are upregulated in the fed state, when 
compared to the fasted group, and also that the administration of the insulin receptor 
antagonist on the fed groups leads to a huge decrease in mRNA levels of both genes. This 
confirms RNA-seq data, validates the hypothesis that there is feeding regulation of these 
genes, and confirms that this effect is due to the action of insulin, since blocking of insulin 
signalling by S961 inhibits the normal increase in transcription of these genes as a result of 
feeding. In the case of Gck, mRNA levels even drop below the basal levels observed in the 
fasted groups when S961 is administered to a fed group. 
 
Figure 14. Effect of feeding and/or S961 on the mRNA expression levels of two feeding-downregulated genes 
– the catalytic subunit of glucose-6-phosphatase, or G6Pc (A), and phosphoenolpyruvate carboxykinase 1, or 
Pck1 (B), in the liver, evaluated by rt-qPCR. Results are shown as group average ± standard deviation.  
 *** p < 0.001 vs. Unfed+PBS;  ** p < 0.01 vs. Unfed+PBS;  
              + p < 0.05 vs. Fed+PBS;   ## p < 0.01 vs. Unfed+S961 
Finally, figure 14 shows the effect of the same treatments on two feeding downregulated 
genes encoding enzymes of gluconeogenesis. Both glucose-6-phosphatase (G6P) and 
phosphoenolpyruvate carboxykinase 1 (Pck1) are key enzymes in the gluconeogenesis 
metabolic pathway, and are thus upregulated during fasting periods, when blood glucose 
levels drop and the liver needs to produce glucose in compensation. G6P also catalyses the 
final step of glycogenolysis that leads to production of glucose through breakdown of hepatic 
glycogen stores. Results show a normal mRNA expression pattern in response to feeding 
and to blocking of insulin signalling by S961: feeding repressed both genes’ mRNA 
expression. For G6Pc (figure 14-A), S961 caused an increase in mRNA levels in fed animals, 
which suggests that insulin was repressing G6Pc in the fed state and blocking of this pathway 
led to reversion of the feeding expression pattern back to fasting levels even after feeding. 
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In the case of Pck1 (figure 14-B), however, S961 only caused a decrease in mRNA levels in 
fasted animals, where insulin signalling should not be prevalent, and no significant 
difference was observed between the fed groups, which may mean that regulation of this 
enzyme by glucagon prevails over insulin. 
Thus, the animal model seems to be working properly, since blood glucose, serum insulin 
and mRNA expression levels of feeding upregulated genes support S961 as an inducer of 
insulin resistance, a hallmark of type II diabetes. 
3.5. ChIP experiment 
PCR results of mRNA levels showed expected expression patterns in response to feeding 
and insulin signalling (demonstrated by IR antagonism induced by S961). Systemic effects 
were also as expected. We thus considered the insulin resistance animal model was working 
properly and was suitable for the study, and a MED1 Chromatin Immunoprecipitation 
(ChIP) experiment was designed to probe for feeding- and insulin-regulated enhancers. 
3.5.1. Primer design for ChIP 
To perform qPCR on the ChIP samples to assess MED1 recruitment to the selected feeding 
upregulated transcriptional enhancers, it was necessary to design the primer sets targeting 
putative feeding regulated enhancers near the the Gck (2 sites), SREBP-1c and PIK3R1 
genes (DNA). For that purpose, I first had to select the sites on which I wanted to check for 
enrichment in MED1. I tried to choose possible regulatory regions (enhancers) that show an 
increase in H3K27 acetylation in response to feeding (unpublished H3K27Ac data from the 
Grøntved group), since this is associated with active enhancers and H3K27 acetylation 
shows some correlation with MED1 recruitment. Even though distant regions from the target 
genes can bridge to the promoter through looping of the chromatin strand, I focused on sites 
close to the gene promoters (transcription start site, TSS) because these are also associated 
with enrichment in H3K27ac and are easier to recognise. The Mediator complex acts as a 
molecular bridge between the activator proteins bound to enhancer sites and the transcription 
initiation complex (including RNA polymerase) bound to the promoter, and thus the 
promoter is the one gene region to which I was sure MED1 would be in close proximity in 
case of recruitment. With that in mind, I used the H3K27Ac Genome Browser tracks shown 
in figure 15 to identify putative regulatory elements. 
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Figure 15. UCSC genome browser tracks showing H3K27 acetylation across three feeding-upregulated genes 
(Gck, SREBP-1c, PIK3R1) on unfed and fed states (1st and 2nd track on each gene, respectively), with the 
selected primer sites highlighted for each gene. 
These tracks show acetylation of the lysine-27 residue of histone H3 (H3K27ac) along the 
genes under analysis (Gck, SREBP-1c and PIK3R1). This illustrates one of the modifications 
in chromatin landscape that elicit transcriptional activation. Peaks of H3K27ac point to 
transcriptionally active sites and are usually located flanking active promoters (at the TSS) 
or more distant enhancer sites. Histone molecules are temporarily dislocated from promoter 
and enhancer sites during active transcription (histone sliding) to allow for binding of RNA 
polymerase or activator proteins3, originating valleys of acetylation on the Genome Browser 
tracks that correspond to open chromatin. Therefore, I tried to locate my primers on the 
valley areas of the tracks, surrounded by peaks of acetylation. The sites chosen for Gck and 
SREBP-1c do show an enrichment in H3K27ac upon feeding, but the primer site for PIK3R1 
seems to have reduced H3K27 acetylation on the fed state, even though it is also strongly 
upregulated by feeding according to RNA-seq data. The other valley region seen on the 
tracks was also tried for primer design, but no options had enough quality to be further tested. 
Details for the designed primers that were ultimately selected are shown below in table 4. 
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Table 4. Specifications of the primer sets designed to analyse MED1 enrichment near the Gck, SREBP-1c and 
PIK3R1 genes in ChIP DNA samples (from mouse livers) through qPCR. 
Gene Oligo Sequence Tm (°C) % GC Any compl. 3’ compl. 
Gc
k 
0k
b Left primer CTGCCCTCCAGGTCTCCCCC 59.96 75.00 4.00 0.00 
Right primer CCCCAACGACCCCTGCTTATCCT 59.99 60.87 2.00 0.00 
Gc
k 
-5
kb
 Left primer GGCCTGGTGAGTGGGAGGTGT 60.11 66.67 4.00 0.00 
Right primer TGTCAGGGTGGGTTCTGCTGTCT 59.49 56.52 3.00 0.00 
Sr
eb
f1
 
Left primer CCGGGGTTACTAGCGGGCGT 60.67 70.00 4.00 0.00 
Right primer GGGGATGGTTGCCTGTGCGG 60.32 70.00 2.00 1.00 
Pi
k3
r1
 
Left primer AGGGAACAGGGGCTGAAGAACACA 59.75 54.17 3.00 0.00 
Right primer ACCAGTCCCGGTGTGCTTTCTCT 59.80 56.52 4.00 0.00 
The resulting primer sets created amplification products located near the Gck (2 sites), 
SREBP-1c and PIK3R1 genes with lengths of 125, 110, 108 and 77 bp, respectively. The 
primer pairs were then tested similarly to the primer pair designed for RT-qPCR in a series 
of dilutions (4x, 16x, 64x, 256x, 1024x, 4096x and 16348x) prepared from a pooled ChIP 
DNA input sample. The selected primer sets had efficacies of 95.0%, 100.5%, 99.9% and 
118%, respectively. Calculation of primer efficacies is exemplified in Appendix B. 
In addition, I used a primer for a non-coding region of the albumin gene (“Albumin no 
DHS”) and a primer located in a heterochromatic intergenic region, that doesn’t select for 
any gene regions (“No Gene”), as negative controls. 
3.5.2. MED1 antibody testing and optimization of the sonication procedure 
In order to maximize recoveries of DNA obtained after chromatin immunoprecipitation with 
a MED1-specific antibody, it was necessary to optimize the sonication procedure done with 
the Covaris ME220 focused-ultrasonicator. We wanted to check if the time-consuming 
nuclei extraction procedure that was in use could be replaced with a simpler whole-cell 
extraction procedure using higher sonication times. Additionally, due to discontinuation of 
polyclonal antibodies by Santa Cruz Biotechnology, Inc., I started testing a new monoclonal 
anti-MED1 antibody from the same company to check if it was a suitable alternative. 
The results for the optimization and testing experiment are shown in figure 16, below. 
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Figure 16. ChIP recovery rates obtained with different extraction/sonication procedures and antibodies, as 
part of the first ChIP experiment (figure 11): whole-cell (WC) extraction with the polyclonal antibody (WC-
pAb); nuclear extraction (NE) with the polyclonal antibody (NE-pAb); WC extraction with the monoclonal 
antibody (WC-mAb) and NE extraction with the monoclonal antibody (NE-mAb). Results are shown as group 
average ± standard deviation. No Gene was the reference site and albumin (no DHS) the negative control. 
From figure 16, there are two comparisons one can make: WC vs. NE (comparing recoveries 
obtained through two different DNA extraction methods and sonication procedures: WC 
refers to extraction from a whole-cell preparation, while NE refers to nuclear extraction, 
after isolation of the nuclei from the homogenised liver samples) and pAb vs. mAb 
(comparing the suitability of the two antibodies – currently used and potential alternative). 
Firstly, comparing the two extraction and sonication procedures, WC and NE (top row of 
figure 16), NE seems to give better quality results than WC, since the nuclei extraction 
method shows higher recovery rates than the ones obtained with the whole-cell method and 
fold induction over “No Gene” is also higher using NE (data not shown), indicating lower 
background. Therefore, I decided to keep using the NE method with shorter sonication times 
in all subsequent ChIP experiments. 
Regarding the antibody testing (pAb vs. mAb), it was concluded that the tested MED1 
monoclonal antibody (H-7, sc-74475) should not replace the polyclonal MED1 antibody (M-
255, sc-8998) currently in use, as it gives much lower recovery rates than those obtained 
with the polyclonal antibody and the analysed sites show about the same enrichment as the 
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negative controls, making them indistinguishable from background signals. The monoclonal 
antibody was then discarded. Further testing of alternatives will be conducted at a later point. 
3.5.3. Analysis of MED1 ChIP data (Fed vs. Unfed experiment) 
As mentioned above, a MED1 Chromatin Immunoprecipitation (ChIP) experiment was 
designed, where Mediator (MED) complex recruitment was analysed. In a first approach, 
DNA samples obtained from this procedure were analysed by qPCR to evaluate potential 
MED1 enrichment in specific sites near feeding upregulated genes. The genes chosen were 
Gck and SREBP-1c (see above), but also phosphatidylinositol 3-kinase regulatory subunit 
alpha (PIK3R1), an enzyme involved in the insulin signalling pathway, as part of the 
phosphorylation cascade; it is activated by IRS proteins and leads to phosphorylation of 
Akt2. Primers were designed so as to be located as close to the promoter region as possible, 
in transcriptionally active regions (see sections 1.3. and 3.5.1.). 
It was decided to do a MED1 ChIP experiment on Unfed+PBS and Fed+PBS groups to check 
if feeding regulation of MED1 recruitment could be observed. With that in mind, I performed 
a ChIP experiment only on the fed and unfed control groups (injected with PBS). On this 
experiment, it was decided to test only two of the genes; Gck (only the -5kb region) and 
SREBP-1c were chosen for their higher fold changes between fed and unfed states on both 
RNA-seq and qPCR results, which led us to predict stronger regulation by feeding. Results 
from this experiment are shown below in figure 17. 
 
Figure 17. Effect of feeding on the MED1 enrichment in four sites of three expected feeding-upregulated genes 
– Gck, SREBP-1c and phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) in the liver, evaluated 
by ChIP-qPCR. Results are shown as individual recoveries (A) and as group average ± standard deviation 
(B). No Gene was used as a reference site. Different letters indicate samples from different animals, while 
samples with the same letter and different numbers correspond to technical replicates split from the same 
sonicated sample and subject to separate, but parallel, IPs. 
 
 52 
From the DNA recovery rates obtained in the individual samples (figure 17-A), it is possible 
to identify two clear outliers, one in each experimental group (samples Unfed B1 and Fed 
A2). However, these outliers are not observed on both technical replicates of the biological 
sample they belong to, and therefore should only reflect some random experimental error 
(probably during the IP or DNA purification steps), not a biological deviation. Looking past 
those two technical outliers, there is a clear tendency for MED1 enrichment on both genes 
on fed animals. However, this tendency does not translate into a significant difference when 
considering the group averages including all technical replicates (figure 17-B) due to the 
presence of the outliers. Variation on MED1 enrichment on “No Gene” should be 
disregarded as DNA concentrations for this region were very low and therefore the high 
threshold cycle (Cp) values can lead to variation in the LightCycler’s readings. That is the 
reason why results are shown as simple recoveries, and not normalized to “No Gene” levels 
(fold induction over NG). These results point to a potential feeding-regulation of Mediator 
recruitment to feeding-upregulated genes’ enhancers. To try to identify some of these 
enhancers, we decided to sequence the DNA samples obtained (see section 3.6.). 
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3.5.4. Confirmation of sonication efficiency on the Fragment Analyzer 
To check the efficiency of sonication and the quality of the ChIP DNA samples for 
subsequent sequencing, I ran a fragment analysis through an automated capillary 
electrophoresis (on the Fragment Analyzer) of the input samples from the MED1 ChIP 
experiment (Unfed vs. Fed). In figure 18, I include an example of the electropherogram 
obtained for each of the experimental groups. 
 
Figure 18. Electropherogram showing size and amount (intensity) of the fragments of DNA 
formed after ChIP (due to sonication) of input samples A4 (A, Fed+PBS) and B3 (B, 
Unfed+PBS). The ladder used was “1kb plus DNA ladder FS-SLR930-U100” and 75 bp (lower 
marker, LM) and 20,000 bp (upper marker, UM) markers were run along with the samples. 
 
It is visible that all the DNA fragments obtained after sonication belong in the range limited 
by the two markers used (between 75 bp and 20,000 bp long). There is a big sonication-
resistant peak corresponding to fragments of about 15,000 bp in size. However, a clear 
sonication peak consisting of fragments around 10 to 500 bp long would be expected and 
these plots don’t clearly show such a peak. Although the amount of sonicated product in this 
size range was too low, this also shows that no over-sonication occurred, and therefore most, 
if not all, DNA fragments potentially isolated with a length of 10 to 500 bp should result 
from sonication of the regions bound to MED1, selected by the antibody during ChIP, and 
not be an artefact caused by excessive sonication leading to random short fragments. For 
that reason, it was decided to proceed to sequencing of the ChIP samples. 
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3.6. ChIP-seq data analysis 
As mentioned above, sequencing was performed on pooled samples from the Fed vs. Unfed 
MED1 ChIP experiment. The outlier samples observed in figure 17 were not included in this 
analysis. I then made 2 pooled samples for each experimental group (Unfed+PBS and 
Fed+PBS), by combining 3 samples to obtain a total of 5 ng of DNA in each pooled sample, 
from which libraries were subsequently prepared for sequencing. Table 5 shows the samples 
that are a part of each pooled sample used for sequencing. 
Table 5. Samples prepared for ChIP-seq, from the MED1 ChIP Fed vs Unfed experiment discussed on 3.5.3. 
Pooled sample ID Samples used Mice included Tissue DNA (ng) 
SM2659 Unfed A1; A2; B2 ZT14 Unfed+PBS A+B Liver 5.0 
SM2660 Unfed C1; C2; D2 ZT14 Unfed+PBS C+D Liver 5.0 
SM2661 Fed A1; B1; B2 ZT14 Fed+PBS A+B Liver 5.0 
SM2662 Fed D1; E1; E2 ZT14 Fed+PBS D+E Liver 5.0 
3.6.1. Library preparation quality control 
After library preparation and before proceeding to sequencing, the samples were run on the 
Fragment Analyzer® to evaluate PCR efficiency and check if the fragments in the target size 
range (200-300 bp) were properly isolated to assess if the libraries generated were of the 
correct size. The results obtained are shown in figure 19. 
 
Figure 19. Electropherogram showing the size of the DNA fragments selected after library 
preparation for ChIP-seq (where fragments in the range of 200 to 300 bp were isolated) of pooled 
samples SM2661 and SM2662 (Fed+PBS) and SM2659 and SM2660 (Unfed+PBS). 
From the electropherogram presented above, it’s possible to verify that, for every sample, 
the peaks correspond to DNA fragments within the intended size range, and they also show 
quite high intensity, indicating that the amount of DNA obtained from PCR amplification 
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should be enough for sequencing. The peak on the left side of the graph indicating small-
sized fragments (approximately 35–43 bp) may point to the presence of non-ligated adapter 
sequences that haven’t been properly removed from the samples during library preparation. 
3.6.2. Analysis of the MED1-enriched regions 
The DNA fragments obtained from MED1 ChIP and subsequently selected for library 
preparation were sequenced to allow for characterisation of the DNA regions associated with 
MED1, through binding with the Mediator-bound activator protein, and possibly identifying 
some of them as novel enhancer sites upregulated by feeding and responsive to insulin. After 
sequencing, all reads were aligned to the mm9 genome using STAR. Unfortunately, 
sequencing provided a relatively low number of uniquely aligned peaks, as less than 5 
million reads per replicate were attained (as opposed to the normal minimum value of 10 to 
15 million reads). This low sequencing yield may be due to the presence of seq-adapters in 
the libraries (that may not have been removed entirely during library preparation). Therefore, 
to perform preliminary data analysis, it was decided to pool sequencing data from the two 
replicates sequenced. To identify MED1 enriched regions of the genome, all sequence data 
from all conditions were pooled to increase the number of sequencing reads used for peak 
calling. This combined data provided approximately 15 million reads in total. Enriched 
regions (peaks) were subsequently identified using HOMER54. 
The distribution of the identified fragments is shown as an MA plot in figure 20. MED1-
enriched regions regulated by feeding are highlighted, with upregulation shown in green, on 
the top part of the plot, and down regulation in red on the bottom. 
 
Figure 20. Distribution of all regions analysed by ChIP-sequencing (ChIP-seq), with feeding-
regulated genes highlighted (fold change > 2). Feeding upregulated genes are shown in green at 
the top of the plot, while feeding down-regulated genes are shown in red at the bottom of the plot. 
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In total, 1156 MED1 peaks were identified. Of those, 134 showed significantly higher MED1 
occupancy in the fed state than in the fasted state (2-fold enrichment), indicative of 
upregulation by feeding (11.6%), while 158 had less MED1 binding on the fed state, 
compared to the unfed, showing downregulation by feeding (13.7%). Two-fold enrichment 
was considered significant, since the low number of reads didn’t allow for adequate 
statistical treatment. Some of the regions differentially enriched in MED1 in response to 
feeding show large fold changes between fed and fasted states. The R-script used to analyse 
ChIP-seq data is shown in Appendix E. 
Examples of MED1 enriched regions are shown in figure 21, as UCSC Genome Browser 
tracks (regions near Gck and Srebp-1c genes are shown). MED1 occupancy along the DNA 
fragments recovered after ChIP (from my previous MED1 ChIP Fed vs. Unfed experiment), 
as well as H3K27 acetylation and DNase accessible regions (DNase hypersensitive sites, 
DHS) profiles from the same genome locations, obtained from previous experiments from 
the Grøntved group, are presented on the tracks below. 
 
Figure 21. UCSC genome browser tracks showing MED1 occupancy (tracks), as well as previously observed 
H3K27 acetylation (tracks D) and DNase I hypersensitive sites (DHS, tracks E) across the two previously 
probed feeding-upregulated genes (Gck, on the left, and SREBP-1c, on the right) on unfed and fed states (as 
annotated on each track). A shows combined reads from both samples of each experimental group; D shows 
the location and organization of the gene. 
As seen in these tracks, the MED1 occupancy pattern correlates well with the previously 
identified feeding upregulated genes, namely Gck and SREBP-1c (the location of the regions 
probed by ChIP-qPCR is marked on figure 21). These two regions show a clear enrichment 
in MED1 occupancy, even considering the low read count. This is in accordance with the 
gene expression patterns expected from the RNA-seq results and also with the tendencies 
observed by qPCR on the Fed vs. Unfed ChIP experiment, that pointed towards enrichment 
of MED1 in the fed state. It is also visible that the gene regions showing highest feeding 
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upregulation in MED1 recruitment coincide with the regions previously chosen for ChIP-
qPCR probing, for which the primer sets were designed (see section 3.5.1.). The PIK3R1 
gene, however, did not show any clear differences in MED1 occupancy between the two 
experimental groups (tracks not shown here). This is quite likely related to the fact that the 
PIK3R1 region selected by the designed primer set showed an abnormal H3K27 acetylation 
pattern on the fed state (see details for the designed primer in section 3.5.1.). The H3K27ac 
(tracks D) show a similar pattern to MED1 occupancy, with the more acetylated regions 
flanking the sites of highest MED1 recruitment, which therefore overlap with the acetylation 
valleys, as explained above due to the mechanism of chromatin remodelling and activation. 
The DNase I hypersensitive sites (DHS), regions of open chromatin that are especially 
susceptible to enzymatic cleavage and associated with active transcription, also concentrated 
on the regions of highest MED1 recruitment. 
Motif analysis was also performed on the differentially regulated MED1 regions. Because 
of the low number of reads, the sequenced fragments were only probed for previously 
identified motif sequences, curated by the HOMER database, as opposed to a de novo 
analysis, where a motif would be derived from the most frequent DNA sequences present in 
the fragments. Tables 6 and 7 shows the top five most enriched sequence motifs identified 
in feeding up- and downregulated MED1-bound fragments, respectively. 
Table 6. Top five identified DNA motifs that show upregulation by feeding. These motifs were recognised by 
comparing DNA sequences from the fragments isolated by MED1 ChIP with previously identified motifs. 
Motif 
Name 
p-
value 
% target 
sequences 
with motif 
% background 
sequences 
with motif 
 
RXR(NR), DR1 10-9 35.16 13.59 
 HNF4a(NR), DR1 10
-8 25.00 8.33 
 FXR(NR), IR1 10
-7 17.97 4.88 
 
PPARE(NR), DR1 10-7 29.69 11.81 
 FOXA1(Forkhead) 10
-6 19.53 6.20 
Feeding-upregulated regions show a clear pattern of motifs showing similar sequences. 
These motifs are usually bound by nuclear factors, namely the factors/activators RXR 
(retinoid X receptor), HNF4 (hepatocyte nuclear factor 4), FXR (farnesoid X receptor, or 
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bile acid receptor), PPAR (peroxisome proliferator-activated receptor) and FOXA1 
(forkhead box protein A1, or hepatocyte nuclear factor 3). The proteins that bind to the 
identified motifs are all nuclear receptors, and can either recruit coactivator or corepressor 
proteins upon binding to their consensus sequences on target genes. Both FXR and PPAR 
interact and form heterodimers with RXR. The fact that the consensus sequences these 
proteins recognise and bind to consist of inverted repeats also points to binding of the 
receptors as dimers. FOXA1 is a transcriptional activator that acts as a pioneer factor to 
direct chromatin remodelling at its target enhancers5. These motifs are in accordance with 
the ones previously identified by the Grøntved group associated with H3K27ac 
(unpublished, data not shown here), and therefore do not represent any novel activator-
binding sites (enhancers) upregulated by feeding and associated with the Mediator complex. 
However, the presence of the previously identified HNF4, FXR and PPAR binding sites 
validates the H3K27ac motifs previously identified, and suggests that these motifs could 
indeed constitute feeding-regulated enhancer sites. With confirmation of these preliminary 
results, implying HNF4, FXR and PPAR as activator proteins involved in feeding- and 
insulin-regulation of gene transcription, targeting of these proteins on new ChIP experiments 
could allow for identification of new enhancers associated with feeding-regulated genes. 
As mentioned above, this analysis was also done for feeding down-regulated fragments, and 
the identified motifs are listed below, in table 7. 
Table 7. Identified DNA motifs that show downregulation by feeding. These motifs were recognised by 
comparing DNA sequences from the fragments isolated by MED1 ChIP with previously identified motifs. 
Motif 
Name 
p-
value 
% target 
sequences 
with motif 
% background 
sequences 
with motif 
 
GRE(NR), IR3 10-14 20.29 1.01 
 GRE(NR), IR3 10
-10 15.49 1.09 
 ARE(NR) 10
-7 17.39 2.33 
 
PGR(NR) 10-4 14.49 2.72 
 PR(NR) 10
-2 27.54 16.01 
Once more, and even more expressively, it is possible to observe that the identified DNA 
motifs are quite similar to each other and are recognised and bound by nuclear receptors: 
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GRE (glucocorticoid response elements), which is bound by the glucocorticoid receptor, 
ARE (AU-rich elements) and PGR/PR (progesterone receptor). As suggested by the 
sequence on the motifs, some of these activators bind to the consensus sequences in a 
dimerized form, similarly to what was observed for the feeding-upregulated motifs. The 
observed motifs suggest regulation of feeding down-regulated gene enhancers by the 
glucocorticoid receptor, which agrees well with previously obtained data from the Grøntved 
group, providing preliminary validation for those results. 
3.7. Analysis of MED1 ChIP data (Fed vs. Fed+S961 experiment) 
A preliminary setup was defined, to check whether insulin signalling influenced MED1 
recruitment to the genes identified to be feeding and insulin-regulated by RNA-seq and 
qPCR. For this purpose, I performed an identical experiment to the one previously described, 
but with the samples from both fed groups (injected with either PBS or S961). Results 
obtained are shown in figure 22. 
 
Figure 22. Effect of insulin antagonist S961 on the MED1 enrichment in four sites of three 
feeding-upregulated genes – Gck, SREBP-1c and phosphatidylinositol 3-kinase regulatory 
subunit alpha (PIK3R1) in the liver, evaluated by ChIP-qPCR. Results are shown as group 
average ± standard deviation. No Gene was the reference site and albumin (no DHS) the 
negative control. + p < 0.05 vs. Fed+PBS. 
Figure 22 shows a significant difference between the two groups only on the upstream 
enhancer site of Gck, but not in any of the other sites. It is possible to see that background 
is not affecting the results since the negative control region (identified as No Gene, or NG, 
a region not used as an enhancer in liver tissue, and thus showing no H3K27Ac) shows a 
DNA recovery rate that is quite low and not comparable to the recoveries obtained with the 
designed primers. Regarding the enhancer of Gck located 5 kb upstream of the gene 
 60 
promoter, one can see that there is enrichment in MED1 on the fed state, where insulin 
signalling is active, compared to the Fed+S961 group, where insulin signalling is blocked, 
mimicking insulin resistance. It should be noted that, even though this difference in MED1 
recruitment is significant, the effect is very small. We hypothesize that Mediator recruitment 
may be regulated by insulin signalling and could therefore be a useful probe for identifying 
transcriptional enhancers subjected to insulin regulation, in a subsequent ChIP-seq 
experiment on these samples. 
3.8. Expression analysis of proteins involved in the insulin signalling pathway 
Expression and activation analysis of proteins involved in the insulin signalling pathway was 
also carried out in liver protein extracts to evaluate the activation of the insulin signalling 
pathway by feeding and the effectiveness of insulin receptor blocking by S961. Results are 
shown in figure 23. 
 
Figure 23. Effect of feeding and/or injection with insulin antagonist S961 on the expression and activation 
(shown as phosphorylation) of insulin receptor subunit b (B) and Akt (C), evaluated by Western blotting. 
Expression of tubulin (A) was used as a loading control. The last lane on each blot corresponds to a positive 
control of the insulin signaling pathway activation by treatment of H4IIE cells with insulin. 
The blots reproduced in figure 23 show that loading of all samples on the electrophoresis 
gels was uniform, since the amount of b-tubulin, which should depend only on the amount 
of total protein, seems to be approximately the same on all lanes (figure 23-A), 
independently of the applied treatment. Similarly, in figures 23-B and 23-C, one can observe 
that amounts of insulin receptor (IR) and Akt, respectively, are approximately the same in 
all experimental groups, as expected. Therefore, differences in the phosphorylated forms of 
these proteins result only from different activation states due to insulin signalling, and are 
not due to differential expression of the native proteins. On the same figures, IR seems to be 
more phosphorylated on the fed state (Fed+PBS) than on either group of the unfed state, 
which results from the increase in insulin levels in the blood after feeding, leading to binding 
to the IR and its consequent activation through phosphorylation. However, there’s no clear 
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effect of S961 on the phosphorylation of this protein. Moreover, if one looks at the results 
for Ser473-phosphorylated Akt (pAkt), it appears quite unexpected. Even though Akt is 
more phosphorylated in the fed state (Fed+PBS vs. Unfed+PBS), which is normal, it is also 
evident that S961 is strongly promoting Akt phosphorylation, in both the fed and fasted 
groups. This observation conflicts with the systemic and transcriptional effects of S961 
observed in the previous experiments as insulin signalling should be blocked in response to 
S961 binding to the IR. It has previously been reported that S961 could show a partial agonist 
behaviour at low concentrations in vitro (1–10 nM), by weakly inducing IR and Akt 
phosphorylation48, but this should not be an issue as the amount of S961 injected should be 
high enough to assure full antagonism of the IR (40 nM/kg, intraperitoneally). In fact, an in 
vivo study in rats showed that a concentration of 10 or 30 nM/kg was enough to elicit the 
systemic effects of insulin resistance (hyperglycaemia, hyperinsulinemia and depletion of 
hepatic glycogen)52. On the other hand, a more recent study focusing on the development of 
a monoclonal antibody alternative to insulin resistance models has now suggested that in the 
presence of increased concentrations of insulin (at 10 and 100 nM), the ability of S961 to 
block phosphorylation of IR and Akt becomes compromised, and levels of both pIR and 
pAkt increase above basal levels47. As seen in figure 11-A, mice injected with S961 became 
hyperinsulinemic, with insulin concentrations reaching 11.5 to 18.4 nM, which surpass the 
10 nM shown to counteract the effects of S961 on Akt phosphorylation. The competitive 
antagonism model could explain that the higher levels of insulin in the blood in response to 
S961 administration would lead to dislocation of S961 and to higher activation of the IR. 
Nevertheless, this should also affect blood glucose and the mRNA expression patterns, but 
these still support the occurrence of insulin resistance induced by S961. 
Thus, the mechanism of action of S961, which leads to blockage of insulin signalling, needs 
to be clarified. With that purpose, I performed further Western blots on the phosphorylation 
of two signalling molecules downstream of pAkt (FOXO1A and glycogen synthase kinase, 
or GSK) to check if their activation was affected in the same way or if it showed the expected 
response to the presence of S961. The results for GSK3b are shown below, in figure 24. 
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Figure 24. Effect of feeding and/or injection with insulin antagonist S961 on the expression 
and activation (shown as phosphorylation) of glycogen synthase kinase 3 isoform b (GSK-
3b), evaluated by Western blotting. The last two lanes on the blot correspond, in order, to 
a positive and a negative control of the insulin signalling pathway activation by treatment 
of H4IIE cells with insulin or from input samples of fasted animals, respectively. 
Figure 24 shows protein expression levels of native GSK and its activation state reflected by 
phosphorylation levels. Native and phosphorylated FOXO1A were also assessed but results 
are not shown here because no bands were detected on the blotted membrane. Once more, 
loading of the wells on the electrophoresis was uniform for all samples, as native GSK 
expression exhibits the same pattern across all samples. Looking at the control lanes for the 
phosphorylated GSK assay, the phosphorylation pattern is not according to expected. GSK 
is an enzyme that inactivates glycogen synthase by promoting its phosphorylation. 
Therefore, since glycogen synthesis is up-regulated in the liver by feeding, when insulin 
signalling is most active, glycogen synthase (GS) is expected to be active after feeding, and 
GSK should be inactive at this time, and active during fasting, inhibiting GS activity when 
available blood glucose is low. GSK is also inactivated by phosphorylation promoted by 
upstream signalling molecules and thus the expected pattern (GSK phosphorylation induced 
by insulin) does not correspond to the results seen on the controls where insulin signalling 
was promoted (positive control, no phosphorylated GSK) and repressed (negative control, 
where high GSK phosphorylation is observed). A troubleshooting experiment was 
performed on the same membrane, by reprobing with pAkt antibody, but no conclusive result 
was obtained, and therefore there are two possible explanations for this observation: 
although unlikely, there may have been a switch of controls during loading, or the 
unexpected phosphorylation pattern could result from an unknown mechanism or response 
to insulin by the cultured cells that may differ from cell behaviour in vivo. However, the 
results for the samples under analysis appear to match the ones observed for pAkt: GSK is 
more phosphorylated in the fed than in the fasted state, as would be expected, but S961 also 
seems to promote phosphorylation of this enzyme, instead of repressing it. 
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Therefore, this additional experiment did not allow to clarify the mechanism by which S961 
seems to agonize phosphorylation patterns of the insulin signalling pathway, but still 
antagonize the effects of insulin on metabolism. A possible mechanism could involve 
different isoforms or subcellular localizations of one or more messenger molecules eliciting 
different cellular effects, as could be the case of Akt isoforms41. These results, in 
combination with the low percentage of S961-sensitive feeding regulated genes observed on 
the RNA-seq data, lead to questioning on whether S961 is the adequate model for full IR 
antagonism and mimicking of insulin resistance and therefore further research on the topic 
is needed. 
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4. Conclusions 
Blood glucose, serum insulin and mRNA expression levels of feeding upregulated genes 
support S961 (an antagonist of the insulin receptor) as an inducer of insulin resistance. 
However, Akt phosphorylation conflicted with systemic and transcriptional effects of S961 
as it stimulated phosphorylation of Akt when insulin signalling should be blocked. Previous 
studies have shown that both low concentrations of S961 and hyperinsulinemia may lead to 
partial agonism of the insulin receptor by S961, due to the competitive binding mechanism. 
Western blots on phosphorylation of downstream signalling molecules (GSK and FOXO1) 
were either inconclusive or showed the same phosphorylation pattern as Akt and did not help 
in clarifying the mechanism of action of S961. Another possibility for explaining the partial 
agonism of S961 at the phosphorylation patterns of insulin-activated second messengers, 
contrasting with its antagonist effects on the metabolic genes, may relate to the different 
isoforms of Akt showing distinct tissue distribution and subcellular localization that can 
affect its function. However, further research would be necessary to elucidate this odd 
behaviour exhibited in response to S961. Future work could then include additional Western 
blotting analyses, complemented by fluorescence microscopy studies of tagged native and 
phosphorylated messengers. This might provide clearer mechanisms to the transduction of 
insulin signalling and to the action of S961 as an antagonist of the insulin receptor. 
MED1 ChIP-qPCR results showed a potential feeding and insulin regulation of recruitment 
of the Mediator complex (a crucial transcriptional coactivator) to enhancers. Sequencing of 
the DNA samples obtained from one of those ChIP experiments (ChIP-seq) allowed to 
preliminarily confirm feeding upregulation of Mediator occupancy near some canonical 
feeding upregulated genes. The identification of DNA motifs within these regions led to no 
new information regarding bound activators, but allowed to validate previously identified 
enhancer motifs for genes upregulated by feeding. However, the number of sequenced reads 
obtained was quite low and thus optimization as well as analysis of a larger number of 
samples (or recovery of a higher amount of DNA) would be important to validate and 
improve the quality of these results. Moreover, due to time limitations, it was not possible 
to undertake further ChIP experiments investigating the regulation of these genes by 
insulin/S961. It would be very interesting to proceed with these analyses and to perform 
supplementary ChIP experiments probing for different transcription factors or activators. 
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Appendix A: R-script for RNA-seq data analysis 
C-2	samples	RNA-seq	data	analysis	
Catarina	M	Correia	
09/02/2017	
Loading	data	
I	want	to	choose	my	.txt	file	with	the	data	I	need	to	analyse.	
# set working directory 
# command is: setwd("folder name") 
 
setwd("~/Documents/Escola/Universidade/Mestrado Bioquímica Clínica – UA/2º Ano, 
Tese, Ano Lectivo 2016:2017/RNA-seq/C-2 samples") 
 
 
# define the file on use and set a name for the data contained 
# command is: set_name = read.delim("file name within the defined directory", h
eader = TRUE, dec = ".", etc.) 
 
seqdata = read.delim("SM1981-SM2001_diffExp output.txt", header = TRUE, dec = "
.") 
 
 
# view your data set 
View(seqdata)     # opens a table with all your data 
names(seqdata)    # gives a list with the names corresponding to each column nu
mber 
##  [1] "Transcript.RepeatID..cmd.analyzeRepeats.pl.rna.mm9..strand.both..count
.exons..d..storage.Grontved.Homer_TagDir.SM1981...storage.Grontved.Homer_TagDir
.SM1982...storage.Grontved.Homer_TagDir.SM1983...storage.Grontved.Homer_TagDir.
SM1987...storage.Grontved.Homer_TagDir.SM1988...storage.Grontved.Homer_TagDir.S
M1989...storage.Grontved.Homer_TagDir.SM1993...storage.Grontved.Homer_TagDir.SM
1994...storage.Grontved.Homer_TagDir.SM1995...storage.Grontved.Homer_TagDir.SM1
999...storage.Grontved.Homer_TagDir.SM2000...storage.Grontved.Homer_TagDir.SM20
01...noadj...cmd.getDiffExpression.pl..data.home.correia.SM1981.SM2001_raw.txt.
ZT14F.ZT14F.ZT14F.ZT14FS961.ZT14FS961.ZT14FS961.ZT14unfed.ZT14unfed.ZT14unfed.Z
T14unfedS961.ZT14unfedS961.ZT14unfedS961..DESeq2." 
##  [2] "chr"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
##  [3] "start"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
##  [4] "end"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
##  [5] "strand"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
##  [6] "Length"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
##  [7] "Copies"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
##  [8] "Annotation.Divergence"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
##  [9] "X.storage.Grontved.Homer_TagDir.SM1981..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [10] "X.storage.Grontved.Homer_TagDir.SM1982..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [11] "X.storage.Grontved.Homer_TagDir.SM1983..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [12] "X.storage.Grontved.Homer_TagDir.SM1987..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [13] "X.storage.Grontved.Homer_TagDir.SM1988..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [14] "X.storage.Grontved.Homer_TagDir.SM1989..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [15] "X.storage.Grontved.Homer_TagDir.SM1993..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [16] "X.storage.Grontved.Homer_TagDir.SM1994..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [17] "X.storage.Grontved.Homer_TagDir.SM1995..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 II 
## [18] "X.storage.Grontved.Homer_TagDir.SM1999..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [19] "X.storage.Grontved.Homer_TagDir.SM2000..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [20] "X.storage.Grontved.Homer_TagDir.SM2001..reads"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [21] "ZT14F.vs..ZT14FS961.baseMean"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
## [22] "ZT14F.vs..ZT14FS961.log2FoldChange"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
## [23] "ZT14F.vs..ZT14FS961.lfcSE"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
## [24] "ZT14F.vs..ZT14FS961.stat"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
## [25] "ZT14F.vs..ZT14FS961.pvalue"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
## [26] "ZT14F.vs..ZT14FS961.padj"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
## [27] "ZT14F.vs..ZT14unfed.baseMean"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
## [28] "ZT14F.vs..ZT14unfed.log2FoldChange"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
## [29] "ZT14F.vs..ZT14unfed.lfcSE"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
## [30] "ZT14F.vs..ZT14unfed.stat"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
## [31] "ZT14F.vs..ZT14unfed.pvalue"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
## [32] "ZT14F.vs..ZT14unfed.padj"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
## [33] "ZT14F.vs..ZT14unfedS961.baseMean"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
## [34] "ZT14F.vs..ZT14unfedS961.log2FoldChange"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
## [35] "ZT14F.vs..ZT14unfedS961.lfcSE"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [36] "ZT14F.vs..ZT14unfedS961.stat"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
## [37] "ZT14F.vs..ZT14unfedS961.pvalue"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
## [38] "ZT14F.vs..ZT14unfedS961.padj"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
## [39] "ZT14FS961.vs..ZT14unfed.baseMean"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
## [40] "ZT14FS961.vs..ZT14unfed.log2FoldChange"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
## [41] "ZT14FS961.vs..ZT14unfed.lfcSE"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
## [42] "ZT14FS961.vs..ZT14unfed.stat"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
## [43] "ZT14FS961.vs..ZT14unfed.pvalue"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
## [44] "ZT14FS961.vs..ZT14unfed.padj"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
## [45] "ZT14FS961.vs..ZT14unfedS961.baseMean"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
## [46] "ZT14FS961.vs..ZT14unfedS961.log2FoldChange"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
## [47] "ZT14FS961.vs..ZT14unfedS961.lfcSE"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
## [48] "ZT14FS961.vs..ZT14unfedS961.stat"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
## [49] "ZT14FS961.vs..ZT14unfedS961.pvalue"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
## [50] "ZT14FS961.vs..ZT14unfedS961.padj"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
## [51] "ZT14unfed.vs..ZT14unfedS961.baseMean"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
## [52] "ZT14unfed.vs..ZT14unfedS961.log2FoldChange"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
## [53] "ZT14unfed.vs..ZT14unfedS961.lfcSE"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
## [54] "ZT14unfed.vs..ZT14unfedS961.stat"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
## [55] "ZT14unfed.vs..ZT14unfedS961.pvalue"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
## [56] "ZT14unfed.vs..ZT14unfedS961.padj" 
Filtering	data	(feeding-regulated	sites)	
Now	 I	 want	 to	 create	 subsets	 of	 data	 containing	 only	 the	 genome	 sites	 that	 are	 regulated	 by	
feeding,	 which	 consists	 of	 the	 genes	 which	 are	 significantly	 differently	 expressed	 (FDR	 <0.05)	
between	the	Fed	and	Unfed	groups	(ZT14F	vs.	ZT14unfed	–	padj).	
# create the subsets you need 
diff_exp = seqdata[ seqdata$ZT14F.vs..ZT14unfed.padj < 0.05, ] 
diff_up = diff_exp[ diff_exp$ZT14F.vs..ZT14unfed.log2FoldChange < 0, ] 
diff_down = diff_exp[ diff_exp$ZT14F.vs..ZT14unfed.log2FoldChange > 0, ] 
 
# next three subsets are inserted in the feeding upregulated genes 
 
ins_reg = diff_up[ diff_up$ZT14F.vs..ZT14FS961.padj < 0.05, ] 
 
ins_up = diff_up[ diff_up$ZT14F.vs..ZT14FS961.padj < 0.05 & diff_up$ZT14F.vs..Z
T14FS961.log2FoldChange < 0, ] 
 III 
 
ins_down = diff_up[ diff_up$ZT14F.vs..ZT14FS961.padj < 0.05 & diff_up$ZT14F.vs.
.ZT14FS961.log2FoldChange > 0, ] 
Plotting	feeding-regulated	data,	MA	plot	
Now,	it's	time	to	plot	all	sequencing	data,	and	highlighting	the	genes	that	are	actually	differentially	
expressed	as	a	consequence	of	the	feeding/fasting	entrainment,	in	order	to	show	the	distribution	
of	 down-	 and	 upregulated	 genes	 by	 feeding.	 I	 want	 downregulated	 genes	 to	 be	 shown	 at	 the	
bottom	of	the	plot	and	 in	red	and	upregulated	genes	to	be	shown	at	the	top	of	the	plot	and	 in	
green.	
# make an MA plot with the unfiltered data 
plot(log2(seqdata$ZT14F.vs..ZT14unfed.baseMean + 1), -seqdata$ZT14F.vs..ZT14unf
ed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/Unf
ed", pch=1, cex=0.7, col="gray", ylim=c(-1,1.5), xlim=c(0,20)) 
 
 
# highlight the feeding-regulated sites 
 
points(log2(diff_up$ZT14F.vs..ZT14unfed.baseMean + 1), -diff_up$ZT14F.vs..ZT14u
nfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/U
nfed", pch=1, cex=0.7, col="darkgreen", ylim=c(-1,1.5), xlim=c(0,20)) 
 
points(log2(diff_down$ZT14F.vs..ZT14unfed.baseMean + 1), -diff_down$ZT14F.vs..Z
T14unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change F
ed/Unfed", pch=1, cex=0.7, col="darkred", ylim=c(-1,1.5), xlim=c(0,20)) 
	
Plotting	insulin-regulated	data,	MA	plot	
Since	my	main	focus	is	the	set	of	genes	upregulated	by	feeding,	now	I	want	to	plot	only	those	and	
highlight	 the	 ones	 that	 are	 also	 differentially	 expressed	 as	 a	 consequence	 of	 insulin	 signaling	
(regulated	by	S961,	an	insulin	antagonist).	With	that	in	mind,	I	decided	to	have	two	different	kinds	
of	plots:	one	that	"zooms	in"	the	feeding-upregulated	region	of	the	main	plot,	using	the	same	axes,	
and	highlights	the	genes	regulated	by	insulin,	in	green;	and	another	that	shows	the	same	data,	but	
with	 the	 differential	 expression	 being	 plotted	 in	 terms	 of	 S961	 effect,	 allowing	 for	 distinction	
between	up-	and	down-regulation	by	S961/insulin.	
# make an MA plot with only the feeding up-regulated data 
plot(log2(diff_up$ZT14F.vs..ZT14unfed.baseMean + 1), -diff_up$ZT14F.vs..ZT14unf
ed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/Unf
 IV 
ed", pch=1, cex=0.7, col="gray", ylim=c(0,1.5), xlim=c(0,20)) 
 
 
# highlight the insulin-regulated sites 
 
points(log2(ins_reg$ZT14F.vs..ZT14unfed.baseMean + 1), -ins_reg$ZT14F.vs..ZT14u
nfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/U
nfed", pch=1, cex=0.7, col="darkgreen", ylim=c(0,1.5), xlim=c(0,20)) 
	
## ANOTHER VIEWING OPTION (to distinguish up- and down-regulation by S961) 
 
# make an MA plot with only the feeding up-regulated data 
plot(log2(diff_up$ZT14F.vs..ZT14FS961.baseMean + 1), -diff_up$ZT14F.vs..ZT14FS9
61.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/Fed
+S961", pch=1, cex=0.7, col="gray", ylim=c(-1.5,1.5), xlim=c(0,20)) 
 
# highlight the insulin-regulated sites 
 
points(log2(ins_reg$ZT14F.vs..ZT14FS961.baseMean + 1), -ins_reg$ZT14F.vs..ZT14F
S961.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/F
ed+S961", pch=1, cex=0.7, col="darkgreen", ylim=c(-1.5,1.5), xlim=c(0,20)) 
	
# identify the 3 genes that are upregulated by S961 ("downregulated" by insulin
) 
 
View(na.omit(ins_up[,7:8]))  # ins_up[,8] is the same as ins_up$Annotation.Dive
 V 
rgence 
View(na.omit(ins_down[,7:8])) 
Note:	Result	of	the	list	of	genes	that	are	insulin-down-regulated	but	feeding-up-regulated	
• Klf10|AI115143|EGR[a]|Egral|Gdnfif|TIEG-1|Tieg|Tieg1|mGIF|-|15	B3.1|15|protein-coding	
• Slc25a30|4933433D23Rik|AV025504|AV221431|AW319655|KMCP1|-|14|14	D2|protein-coding	
• E2f8|4432406C08Rik|AA410048|-|7	B4|7|protein-coding	
Extra	Plots	on	Insulin	Regulation	
I	want	to	illustrate	the	insulin	regulated	genes	now,	independently	of	up-	or	down-regulation	by	
feeding	and	also	check	whether	any	insulin-regulated	genes	are	independent	from	feeding	(which	
could	be	due	to	activation	of	alternative	signalling	pathways).	
# make an MA plot showing all genes that are insulin-regulated on the main plot 
 
plot(log2(seqdata$ZT14F.vs..ZT14unfed.baseMean + 1), -seqdata$ZT14F.vs..ZT14unf
ed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/Unf
ed", pch=1, cex=0.7, col="gray", ylim=c(-1,1.5), xlim=c(0,20)) 
 
all_ins_reg = seqdata[ seqdata$ZT14F.vs..ZT14FS961.padj < 0.05, ] 
ins_feed_reg = diff_exp[ diff_exp$ZT14F.vs..ZT14FS961.padj < 0.05, ] 
 
points(log2(all_ins_reg$ZT14F.vs..ZT14unfed.baseMean + 1), -all_ins_reg$ZT14F.v
s..ZT14unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold chan
ge Fed/Unfed", pch=1, cex=0.7, col="lightblue", ylim=c(-1,1.5), xlim=c(0,20)) 
 
points(log2(ins_feed_reg$ZT14F.vs..ZT14unfed.baseMean + 1),-ins_feed_reg$ZT14F.
vs..ZT14unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold cha
nge Fed/Unfed", pch=1, cex=0.7, col="slateblue4", ylim=c(-1,1.5), xlim=c(0,20)) 
	
# make an MA plot showing insulin-regulated genes not feeding-regulated 
 
plot(log2(seqdata$ZT14F.vs..ZT14unfed.baseMean + 1), -seqdata$ZT14F.vs..ZT14unf
ed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/Unf
ed", pch=1, cex=0.7, col="gray", ylim=c(-1,1.5), xlim=c(0,20)) 
 
ins_reg_not_feed = seqdata[ seqdata$ZT14F.vs..ZT14FS961.padj < 0.05 & seqdata$Z
T14F.vs..ZT14unfed.padj > 0.05, ] 
 
points(log2(ins_reg_not_feed$ZT14F.vs..ZT14unfed.baseMean + 1),-ins_reg_not_fee
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d$ZT14F.vs..ZT14unfed.log2FoldChange,xlab="log2(Mean tag density)", ylab="log2f
old change Fed/Unfed", pch=1, cex=0.7, col="red", ylim=c(-1,1.5), xlim=c(0,20)) 
	
# make a merged version of the plots that show feeding-regulation and insulin-r
egulation 
 
plot(log2(seqdata$ZT14F.vs..ZT14unfed.baseMean + 1), -seqdata$ZT14F.vs..ZT14unf
ed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/Unf
ed", pch=1, cex=0.7, col=adjustcolor("gray", alpha.f = 0.2), ylim=c(-1,1.5), xl
im=c(0,20)) 
 
points(log2(diff_up$ZT14F.vs..ZT14unfed.baseMean + 1), -diff_up$ZT14F.vs..ZT14u
nfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed/U
nfed", pch=1, cex=0.7, col=adjustcolor("darkgreen", alpha.f = 0.2), ylim=c(-1,1
.5), xlim=c(0,20)) 
 
points(log2(diff_down$ZT14F.vs..ZT14unfed.baseMean + 1), -diff_down$ZT14F.vs..Z
T14unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change F
ed/Unfed", pch=1, cex=0.7, col=adjustcolor("darkred", alpha.f = 0.2), ylim=c(-1
,1.5), xlim=c(0,20)) 
 
points(log2(all_ins_reg$ZT14F.vs..ZT14unfed.baseMean + 1), -all_ins_reg$ZT14F.v
s..ZT14unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold chan
ge Fed/Unfed", pch=1, cex=0.7, col="slateblue4", ylim=c(-1,1.5), xlim=c(0,20)) 
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We	can	see	from	the	last	two	graphs	that	there	are	quite	a	few	genes	that	are	not	differentially	
expressed	by	feeding	but	still	regulated	by	insulin,	since	on	the	there	is	a	set	of	plotted	points	shown	
in	red,	and	on	the	second	not	one	all	dark	blue	points	overlap	with	red	or	green	points.	
Extra	Plots	on	Feeding-downregulated	genes	
In	this	last	section,	I	want	to	make	the	same	kind	of	plots	I	had	for	feeding	upregulated	genes,	but	
on	the	downregulated	subset.	
# make an MA plot with only the feeding down-regulated data 
plot(log2(diff_down$ZT14F.vs..ZT14unfed.baseMean + 1), -diff_down$ZT14F.vs..ZT1
4unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed
/Unfed", pch=1, cex=0.7, col="gray", ylim=c(-1,0), xlim=c(0,20)) 
 
 
# highlight the insulin-regulated sites 
 
ins_reg_feed_down = diff_down[ diff_down$ZT14F.vs..ZT14FS961.padj < 0.05, ] 
 
points(log2(ins_reg_feed_down$ZT14F.vs..ZT14unfed.baseMean + 1), -ins_reg_feed_
down$ZT14F.vs..ZT14unfed.log2FoldChange, xlab="log2(Mean tag density)", ylab="l
og2fold change Fed/Unfed", pch=1, cex=0.7, col="darkgreen", ylim=c(-1,0), xlim=
c(0,20)) 
	
## ANOTHER VIEWING OPTION (to distinguish up- and down-regulation by S961) 
 
# make an MA plot with only the feeding down-regulated data 
plot(log2(diff_down$ZT14F.vs..ZT14FS961.baseMean + 1), -diff_down$ZT14F.vs..ZT1
4FS961.log2FoldChange, xlab="log2(Mean tag density)", ylab="log2fold change Fed
/Fed+S961", pch=1, cex=0.7, col="gray", ylim=c(-1.5,1.5), xlim=c(0,20)) 
 
# highlight the insulin-regulated sites 
 
points(log2(ins_reg_feed_down$ZT14F.vs..ZT14FS961.baseMean + 1), -ins_reg_feed_
down$ZT14F.vs..ZT14FS961.log2FoldChange, xlab="log2(Mean tag density)", ylab="l
og2fold change Fed/Fed+S961", pch=1, cex=0.7, col="darkgreen", ylim=c(-1.5,1.5)
, xlim=c(0,20)) 
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# identify the 2 genes that are downregulated by S961 ("upregulated" by insulin
) 
 
ins_up_feed_down = diff_down[ diff_down$ZT14F.vs..ZT14FS961.padj < 0.05 & diff_
down$ZT14F.vs..ZT14FS961.log2FoldChange < 0, ] 
ins_down_feed_down = diff_down[ diff_down$ZT14F.vs..ZT14FS961.padj < 0.05 & dif
f_down$ZT14F.vs..ZT14FS961.log2FoldChange > 0, ] 
 
View(na.omit(ins_up_feed_down[,7:8])) 
View(na.omit(ins_down_feed_down[,7:8])) 
Note:	Result	of	the	list	of	genes	that	are	insulin-up-regulated	but	feeding-down-regulated	
• Tsc22d3|DIP|Dsip1|Gilz|TSC-22R|Tilz3|RP23-440B21.1|X	F1|X|protein-coding	
• Tsc22d3|DIP|Dsip1|Gilz|TSC-22R|Tilz3|RP23-440B21.1|X	F1|X|protein-coding	
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Appendix B: Example calculation of primer efficiency (primer testing) 
Primer set mSREBP-1c + 10.1 kb 
Primer test, 08/12/2016 
Test material: AK100 (ChIP), pooled input samples 
Table B-1. qPCR threshold cycle (Cp) values for a series of dilutions of a pooled ChIP DNA input sample, 
used to trace a calibration curve for determining the efficiency of the tested primer set. 
Sample Cp1 Cp2 Average Dilution factor Log (dil. factor) 
4x 24.46 24.46 24.46 0.2500 -0.6021 
16x 26.44 26.23 26.34 0.0625 -1.2041 
64x 28.19 28.25 28.22 0.0156 -1.8062 
256x 30.44 30.57 30.51 0.0039 -2.4082 
1024x 31.62 31.82 31.72 0.0010 -3.0103 
4096x 34.32 34.01 34.17 0.0002 -3.6124 
16348x 37.09 36.41 36.75 0.0001 -4.2135 
NTC 40.00     
 
 
Figure B-1. Calibration curve for the determination of qPCR primer efficiency, using the values presented in 
Table B-1. 
Primer efficiency can then be calculated from the slope of the plotted curve: 
 10	-	 1slope	-	1	= 10	-	 1-3.3242	-	1	=	0.9990	=	99.9% 
 X 
Appendix C: Example calibration curve for total protein quantification 
Table C-1. Absorbance values (at 562 nm) for standard solutions 
with different BSA concentrations, used to trace a calibration curve 
for quantifying total proteins in liver extracts. 
Standards BSA Conc. (ug/uL) OD (562 nm) 
A 4.0 0.881 
 4.0 0.869 
B 2.0 0.528 
 2.0 0.518 
C 1.0 0.345 
 1.0 0.343 
D 0.5 0.244 
 0.5 0.241 
E 0.25 0.193 
 0.25 0.178 
F 0.125 0.151 
 0.125 0.145 
G 0.0625 0.129 
 0.0625 0.128 
H 0.0 0.100 
 0.0 0.097 
 
Figure C-1. Calibration curve for the quantification of total proteins in liver extracts, using the values 
presented in Table C-1. 
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Appendix D: Example calibration curve for DNA quantification (picogreen) 
Table D-1. Fluorescence values for standard solutions with different l-DNA concentrations, used to trace a 
calibration curve for quantifying DNA in liver extracts subjected to ChIP. 
Standard Conc. (ng/ul) Fluorescence 1 Fluorescence 2 Average Excl. background 
A 0.00 304 307 305.5 0 
B 0.25 542 551 546.5 241.0 
C 0.50 775 746 760.5 455.0 
D 1.00 1312 1134 1223 917.5 
E 1.25 1145 1252 1198.5 893.0 
F 2.50 2538 2181 2359.5 2054.0 
G 5.00 4712 4368 4540 4234.5 
H 10.00 9086 8732 8909 8603.5 
 
Figure D-1. Calibration curve for the quantification of DNA in samples obtained after performing ChIP on 
liver extracts, using the values presented in Table D-1. 
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Appendix E: R-script for ChIP-seq data analysis 
MUS12	MED1	ChIP-seq	
Catarina	M	Correia	
26/05/2017	
Loading	data	
I	want	to	choose	my	.txt	file	with	the	data	I	need	to	analyse.	
# set working directory 
setwd("~/…") 
 
# define the file on use and set a name for the data contained 
data= read.delim("MED1_combined_peaks_MED1_tagcount.txt", header=TRUE, dec=".") 
 
# format and view your data set 
rownames(data) <- data[,1] 
data[,1] <- NULL 
data <- subset(data, select=c(1:3,19:20)) 
colnames(data)=c("chr","start","end","unfed","fed") 
data$FC <- log2(data$fed/data$unfed) 
data$mean <- rowMeans(data[,4:5]) 
 
View(data)    # opens a table with all your data 
names(data)   # gives a list with the names corresponding to each column number 
## [1] "chr"   "start" "end"   "unfed" "fed"   "FC"    "mean" 
Filtering	data	(feeding-regulated	sites)	
Create	 subsets	 of	 data	 containing	 only	 the	 genome	 sites	 that	 are	 regulated	 by	 feeding,	 which	
consists	of	the	genes	which	are	significantly	differently	expressed	(fed/unfed	>	2).	
# create the subsets you need 
diff_up = data[ data$FC > 1, ] 
diff_down = data[ data$FC < -1, ] 
Plotting	feeding-regulated	data,	MA	plot	
Plot	all	sequencing	data,	highlighting	differentially	expressed	genes	as	a	result	of	feeding/fasting	
entrainment,	to	show	the	distribution	of	down-	and	upregulated	genes	by	feeding.	Downregulated	
genes	are	to	be	shown	at	the	bottom	of	the	plot	in	red;	upregulated	genes	at	the	top	in	green.	
# make an MA plot with the unfiltered data 
plot(log2(data$mean), data$FC, xlab="log2(Mean tag density)", ylab="log2fold ch
ange Fed/Unfed", pch=1, cex=0.7, col="gray", xlim=c(3,9), ylim=c(-4,4)) 
 
# highlight the feeding-regulated sites 
points(log2(diff_up$mean),diff_up$FC, xlab="log2(Mean tag density)", ylab="log2
fold change Fed/Unfed", pch=1, cex=0.7, col="darkgreen", xlim=c(3,9), ylim=c(-4
,4)) 
 
points(log2(diff_down$mean),diff_down$FC, xlab="log2(Mean tag density)", ylab="
log2fold change Fed/Unfed", pch=1, cex=0.7, col="darkred", xlim=c(3,9), ylim=c(
-4,4)) 
